var title_f27_6_27744="Pregnancy gingivitis";
var content_f27_6_27744=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gingivitis during pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hormonal changes that occur with pregnancy significantly influence the bacterial flora, causing significant gingival inflammation and hypertrophy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mark S Obernesser, DDS, MMSc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_6_27744=[""].join("\n");
var outline_f27_6_27744=null;
var title_f27_6_27745="Longitudinal melanonychia - thumbs";
var content_f27_6_27745=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Longitudinal melanonychia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple pigmented linear streaks on the nail are common in individuals in dark skin. The wart on the proximal nail fold of the thumb on the left is an unrelated finding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_6_27745=[""].join("\n");
var outline_f27_6_27745=null;
var title_f27_6_27746="Pratt cervical dilators";
var content_f27_6_27746=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pratt cervical dilators (uterine cervix)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 412px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_6_27746=[""].join("\n");
var outline_f27_6_27746=null;
var title_f27_6_27747="Pulmonary regurgitation";
var content_f27_6_27747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 592px\">",
"   <div class=\"ttl\">",
"    Pulmonary regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 572px; height: 399px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Continuous wave Doppler signal showing pulmonary regurgitation. The velocity of the regurgitant jet at the end of diastole (after the a wave) represents the end-diastolic pressure gradient between pulmonary artery and right ventricle. Adding right atrial pressure gives an estimate of pulmonary artery diastolic pressure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_6_27747=[""].join("\n");
var outline_f27_6_27747=null;
var title_f27_6_27748="Basic shoulder anatomy posterior view";
var content_f27_6_27748=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Posterior view of shoulder anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 456px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_6_27748=[""].join("\n");
var outline_f27_6_27748=null;
var title_f27_6_27749="Dicyclomine (dicycloverine): Drug information";
var content_f27_6_27749=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dicyclomine (dicycloverine): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/8/32900?source=see_link\">",
"    see \"Dicyclomine (dicycloverine): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/22/16740?source=see_link\">",
"    see \"Dicyclomine (dicycloverine): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F159572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bentyl&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F159573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Bentylol&reg;;",
"     </li>",
"     <li>",
"      Dicyclomine Hydrochloride Injection;",
"     </li>",
"     <li>",
"      Formulex&reg;;",
"     </li>",
"     <li>",
"      Jamp-Dicyclomine;",
"     </li>",
"     <li>",
"      Protylol;",
"     </li>",
"     <li>",
"      Riva-Dicyclomine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F159591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticholinergic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F159576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Gastrointestinal motility disorders/irritable bowel:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Initial: 20 mg 4 times daily for 7 days; after 1 week, may increase to 40 mg 4 times daily. If efficacy not achieved in 2 weeks or if adverse effects require a dose &lt;80 mg/day, therapy should be discontinued. Safety data are not available for doses &gt;80 mg daily for a duration that exceeds 2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.",
"     <b>",
"      (should not be used I.V.)",
"     </b>",
"     : 10-20 mg 4 times daily for 1-2 days; convert to oral therapy as soon as possible",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F159577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use caution; lower dosages may be required.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15666678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15666679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F159552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bentyl&reg;: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bentyl&reg;: 10 mg/mL (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as hydrochloride: 10 mg/5 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bentyl&reg;: 10 mg/5 mL (480 mL [DSC]) [contains propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bentyl&reg;: 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F159537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F159555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injection solution:",
"     <b>",
"      Do not administer I.V.",
"     </b>",
"     ; administer as I.M. injection only.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F159554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of functional bowel/irritable bowel syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F159598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dicyclomine may be confused with diphenhydrAMINE, doxycycline, dyclonine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Bentyl&reg; may be confused with Aventyl&reg;, Benadryl&reg;, Bontril&reg;, Cantil&reg;, Proventil&reg;, TRENtal&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F159589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (40%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (33%), nausea (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (27%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (9%), nervousness (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports with dicyclomine: Abdominal distension, abdominal pain, anaphylactic shock, angioedema, confusional state, constipation, cycloplegia, delirium, dermatitis (allergic), hypersensitivity, dyspepsia, dyspnea, erythema, facial edema, fatigue, hallucinations, headache, insomnia, lactation suppressed, malaise, mydriasis, nasal congestion, palpitation, rash, syncope, tachyarrhythmias, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports with similar anticholinergic drugs: Anorexia, apnea, diaphoresis decreased, diplopia, focal coagulation necrosis (I.M. injection), dyskinesia, hypertension, impotence, itching, lightheadedness (transient), numbness, ocular tension increased, sneezing, speech disorder, throat congestion, tingling, urinary hesitancy, urinary retention (in patients with prostatic hypertrophy), urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F159558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Obstructive diseases of the GI tract; severe ulcerative colitis; reflux esophagitis; unstable cardiovascular status in acute hemorrhage; obstructive uropathy; glaucoma; myasthenia gravis; breast-feeding; infants &lt;6 months of age",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to dicyclomine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F159541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diarrhea: May be a sign of incomplete intestinal obstruction, treatment should be discontinued if this occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heat prostration: May occur in the presence of increased environmental temperature; use caution in hot weather and/or exercise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychosis/delirium: Has been reported in patients with an extreme sensitivity to anticholinergic effects or at excessive dosages, such as the elderly or patients with mental illness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with coronary artery disease, tachyarrhythmias, heart failure, or hypertension; evaluate tachycardia prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropathy: Use with caution in patients with autonomic neuropathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia: Use with caution in patients with prostatic hyperplasia (known or suspected).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Salmonella dysentery: Do not use anticholinergic agents in patients with salmonella dysentery; toxic dilatation of intestine and intestinal perforation may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ulcerative colitis: Use with caution in patients with mild-moderate ulcerative colitis. Use is contraindicated in patients with severe ulcerative colitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid long term use in this age group due to potent anticholinergic effects and uncertain effectiveness (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Serious respiratory reactions, central nervous symptoms, and deaths have been reported following administration to infants; use in infants &lt;6 months of age is contraindicated).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate administration: Injectable formulation is for I.M. administration only; inadvertent I.V. administration may cause thrombosis/thrombophlebitis and injection site reactions (eg, pain, edema, skin color change, reflex sympathetic dystrophy).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F159546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F159569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F159548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4370436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have not been observed in animal reproduction studies. In epidemiologic studies, birth defects were not observed in pregnant women taking doses up to 40 mg daily; information has not been located when used in pregnant women at recommended doses (80-160 mg daily). Use for the treatment of irritable bowel syndrome (IBS) is not recommended during pregnancy (Mahadevan, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F159581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15873837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dicyclomine enters breast milk; use in nursing women is contraindicated. In addition, anticholinergics may suppress lactation.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F159560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Bentyl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $47.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Dicyclomine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $26.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Bentyl Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (2 mL): $43.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Dicyclomine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/5 mL (473 mL): $46.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Bentyl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $68.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Dicyclomine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $35.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F159550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pulse, anticholinergic effect, urinary output, GI symptoms",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F159561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Babypasmil (AR);",
"     </li>",
"     <li>",
"      Bentyl (BR, MX, TW);",
"     </li>",
"     <li>",
"      Blisscolic (PK);",
"     </li>",
"     <li>",
"      Coligon (IN);",
"     </li>",
"     <li>",
"      Cyclominol (IN);",
"     </li>",
"     <li>",
"      Dicymine (HK, TH);",
"     </li>",
"     <li>",
"      Merbentyl (GB, NZ);",
"     </li>",
"     <li>",
"      Nomcramp (ZA);",
"     </li>",
"     <li>",
"      Notensyl (IL);",
"     </li>",
"     <li>",
"      Spasdon Drops (PH);",
"     </li>",
"     <li>",
"      Spatomin (KP);",
"     </li>",
"     <li>",
"      Swityl (TW);",
"     </li>",
"     <li>",
"      Trigan (RU);",
"     </li>",
"     <li>",
"      Wintyl (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F159540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks the action of acetylcholine at parasympathetic sites in smooth muscle, secretory glands and the CNS",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F159557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid and well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3.65 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Initial phase: ~1.8 hours; Terminal phase: Undetermined, but somewhat longer than the initial phase",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral: 60-90 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (80%, small amounts as unchanged drug); feces (8%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/6/27749/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahadevan U and Kane S, \"American Gastroenterological Association Institute Medical Position Statement on the Use of Gastrointestinal Medications in Pregnancy,\"",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 131(1):278-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/6/27749/abstract-text/16831610/pubmed\" id=\"16831610\" target=\"_blank\">",
"        16831610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9350 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-EFEE8658EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_6_27749=[""].join("\n");
var outline_f27_6_27749=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159572\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159573\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159591\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159576\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159577\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15666678\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15666679\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159552\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159537\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159555\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159554\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159598\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159589\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159558\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159541\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299186\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159546\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159569\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159548\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4370436\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159581\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15873837\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159560\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159550\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159561\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159540\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159557\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9350\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9350|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/8/32900?source=related_link\">",
"      Dicyclomine (dicycloverine): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/22/16740?source=related_link\">",
"      Dicyclomine (dicycloverine): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_6_27750="Oxford tubal ligation";
var content_f27_6_27750=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Oxford tubal ligation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 632px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_6_27750=[""].join("\n");
var outline_f27_6_27750=null;
var title_f27_6_27751="Preseptal cellulitis";
var content_f27_6_27751=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Preseptal cellulitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/6/27751/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/6/27751/contributors\">",
"     Christopher Gappy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/6/27751/contributors\">",
"     Steven M Archer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/6/27751/contributors\">",
"     Michael Barza, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/6/27751/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/6/27751/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/6/27751/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/6/27751/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/6/27751/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/6/27751/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/6/27751/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H83430247\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preseptal cellulitis (sometimes called periorbital cellulitis) is an infection of the anterior portion of the eyelid, not involving the orbit or other ocular structures. In contrast, orbital cellulitis is an infection involving the contents of the orbit (fat and ocular muscles), but not the globe. Although preseptal and orbital cellulitis may be confused with one another because both can cause ocular pain and eyelid swelling and erythema, they have very different clinical implications. Preseptal cellulitis is generally a mild condition that rarely leads to serious complications, whereas orbital cellulitis may cause loss of vision and even loss of life. Orbital cellulitis can usually be distinguished from preseptal cellulitis by its clinical features (ophthalmoplegia, pain with eye movements, and proptosis) and by imaging studies. In cases in which the distinction is not clear, clinicians should treat patients as though they have orbital cellulitis. Both conditions are more common in children than in adults, and preseptal cellulitis is much more common than orbital cellulitis.",
"   </p>",
"   <p>",
"    The pathogenesis, microbiology, clinical manifestations, diagnosis, and treatment of preseptal cellulitis will be reviewed here. Orbital cellulitis and its complications, such as subperiosteal abscess and orbital abscess, are discussed separately. Orbital infections caused by fungi, mainly the Mucorales (which cause mucormycosis) and Aspergillus spp, and, much more rarely, Mycobacterium tuberculosis, are also presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link\">",
"     \"Orbital cellulitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link\">",
"     \"Mucormycosis (zygomycosis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5767?source=see_link\">",
"     \"Tuberculosis and the eye\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83430254\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preseptal cellulitis and orbital cellulitis involve different anatomic sites, with preseptal cellulitis referring to infections of the soft tissues anterior to the orbital septum and orbital cellulitis referring to infections posterior to it (",
"    <a class=\"graphic graphic_figure graphicRef68971 \" href=\"UTD.htm?18/7/18550\">",
"     figure 1",
"    </a>",
"    ). Neither infection involves the globe. (See",
"    <a class=\"local\" href=\"#H83430261\">",
"     'Anatomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is some debate regarding the appropriate terminology for these infections. Some clinicians use the term &ldquo;periorbital cellulitis&rdquo; rather than &ldquo;preseptal cellulitis&rdquo; or use the terms interchangeably. We prefer the term &ldquo;preseptal cellulitis&rdquo; to make a clear distinction between this infection and the more serious infection, &ldquo;orbital cellulitis.&rdquo; Orbital cellulitis is sometimes referred to as &ldquo;postseptal cellulitis&rdquo;; we favor the term &ldquo;orbital cellulitis,&rdquo; and will use it throughout this topic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83430261\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basic familiarity with the anatomy of the eye is fundamental to understanding the pathogenesis, clinical manifestations, and complications of preseptal and orbital cellulitis. The orbit is a cone-shaped structure, lying horizontally, with its apex in the skull. It is surrounded by paranasal sinuses, namely, the frontal (lying superior), ethmoid (medial) and maxillary (inferior) sinuses (",
"    <a class=\"graphic graphic_figure graphicRef71411 \" href=\"UTD.htm?20/4/20547\">",
"     figure 2",
"    </a>",
"    ). The orbit is lined by periosteum. The ethmoid sinuses are separated from the orbit by a paper-thin layer called the lamina papyracea, which contains many perforations for nerves and blood vessels as well as some natural fenestrations termed Zuckerkandl&rsquo;s dehiscences. The most common route of infection of the orbit is by extension from the ethmoid sinuses, presumably through these perforations.",
"   </p>",
"   <p>",
"    The orbital septum is a membranous sheet that extends from the periosteum of the orbit to the tarsal plate and forms the anterior boundary of the orbital compartment (",
"    <a class=\"graphic graphic_figure graphicRef68971 \" href=\"UTD.htm?18/7/18550\">",
"     figure 1",
"    </a>",
"    ). As noted above, preseptal cellulitis involves the soft tissues anterior to the orbital septum. The superior and inferior ophthalmic veins drain blood directly into the cavernous sinus (",
"    <a class=\"graphic graphic_figure graphicRef61214 \" href=\"UTD.htm?0/51/821\">",
"     figure 3",
"    </a>",
"    ). Because of this communication and because the inferior orbital veins are valveless, infection can pass readily from the orbit to intracranial structures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234333111\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preseptal cellulitis is much more common than orbital cellulitis. In two pediatric case series, 94 percent and 87 percent of cases, respectively, were diagnosed as preseptal cellulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]; the remainder of cases were diagnosed as orbital cellulitis. Both infections are much more common in children than in adults; accordingly, most of the data regarding these infections comes from studies in children.",
"   </p>",
"   <p>",
"    It is important to distinguish between preseptal and orbital cellulitis because the complications, treatments, and outcomes of the two entities are very different. (See",
"    <a class=\"local\" href=\"#H83430770\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83430756\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whereas the paranasal sinuses are the main source of infection in orbital cellulitis, many cases of preseptal cellulitis (the proportion varying from study to study) arise from external sources. In one retrospective series of 315 children admitted to the hospital with preseptal or orbital cellulitis, sinusitis was the underlying condition in all 18 children with orbital cellulitis, but in only 15 percent of those with preseptal cellulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/2\">",
"     2",
"    </a>",
"    ]. However, other studies have found sinusitis to be the most common cause of preseptal cellulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other sites from which preseptal cellulitis may arise are the surrounding tissues of the face and eyelids following local trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], insect bites [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/7\">",
"     7",
"    </a>",
"    ], animal bites [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/8\">",
"     8",
"    </a>",
"    ], or foreign bodies. In one retrospective series of 104 patients with preseptal cellulitis admitted to a tertiary care center, roughly 30 percent were thought to originate from each of the following causes: acute dacryocystitis, sinusitis or upper respiratory tract infection, or trauma (including recent eyelid or strabismus surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/9\">",
"     9",
"    </a>",
"    ]. In another retrospective study that included 262 children with preseptal or orbital cellulitis, trauma (including insect bites) was much more common in patients with preseptal cellulitis than in those with orbital cellulitis (40 versus 11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/3\">",
"     3",
"    </a>",
"    ]. Bacteremic seeding of the preseptal space is rare. It is occasionally seen in infants with bacteremia due to Streptococcus pneumoniae, Streptococcus pyogenes, or Haemophilus influenza.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83430763\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data concerning the causes of preseptal cellulitis are limited. Blood cultures are almost always negative, and it is usually difficult to obtain cultures from the infected site. Based on the available data, the most common causes of preseptal cellulitis are Staphylococcus aureus, Streptococcus pneumoniae, other streptococci, and anaerobes (",
"    <a class=\"graphic graphic_table graphicRef77104 \" href=\"UTD.htm?35/15/36094\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/3,9\">",
"     3,9",
"    </a>",
"    ], presumably depending on the site of origin of the infection.",
"   </p>",
"   <p>",
"    Of S. aureus strains, community-acquired methicillin-resistant S. aureus (CA-MRSA) is thought to be an increasingly common cause of infection. Although most cases of preseptal cellulitis caused by CA-MRSA have been published only as case reports or retrospective series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], the proportion of other skin and soft tissue infections caused by CA-MRSA has increased dramatically. In a report of 422 adults presenting to emergency departments in 11 United States cities in 2004 with skin and soft tissue infections, 59 percent were caused by MRSA and 97 percent of cases of MRSA were caused by CA-MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\", section on 'Community-associated methicillin-resistant Staphylococcus aureus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although Haemophilus influenzae was previously a common cause of preseptal cellulitis, routine immunization of children with the H. influenzae type b vaccine has caused a sharp decline in the incidence of this species as a cause of preseptal cellulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41608?source=see_link\">",
"     \"Microbiology, epidemiology and treatment of Haemophilus influenzae\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infrequent causes of preseptal cellulitis include Acinetobacter species [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], Nocardia brasiliensis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/15\">",
"     15",
"    </a>",
"    ], Bacillus anthracis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/16\">",
"     16",
"    </a>",
"    ], Pseudomonas aeruginosa [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/17\">",
"     17",
"    </a>",
"    ], Neisseria gonorrhoeae [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/18\">",
"     18",
"    </a>",
"    ], Proteus spp [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/19\">",
"     19",
"    </a>",
"    ], Pasteurella multocida [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/8\">",
"     8",
"    </a>",
"    ], Mycobacterium tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/20\">",
"     20",
"    </a>",
"    ], and Trichophyton spp (the cause of &ldquo;ringworm&rdquo;) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/21\">",
"     21",
"    </a>",
"    ]. These pathogens can usually be linked to specific exposures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83430770\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with preseptal cellulitis typically present with ocular pain, eyelid swelling, and erythema (",
"    <a class=\"graphic graphic_picture graphicRef57604 \" href=\"UTD.htm?9/28/9670\">",
"     picture 1",
"    </a>",
"    ); importantly, preseptal and orbital cellulitis may be confused with one another because both infections can cause these manifestations, but they have very different clinical implications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/3,22-25\">",
"     3,22-25",
"    </a>",
"    ]. In contrast to preseptal cellulitis, orbital cellulitis causes swelling and inflammation of the extraocular muscles and fatty tissues within the orbit, leading to pain with eye movements, proptosis, and ophthalmoplegia with diplopia. Chemosis (conjunctival swelling) may occasionally occur in severe cases of preseptal cellulitis, but is more common with orbital cellulitis. Orbital cellulitis, but not preseptal cellulitis, may cause visual impairment. In a retrospective study that included 262 children, fever occurred more commonly in those with orbital cellulitis than in those with preseptal cellulitis (94 versus 47 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/3\">",
"     3",
"    </a>",
"    ]. Leukocytosis may be present in patients with preseptal cellulitis, but is not a sensitive indicator of this infection. The clinical manifestations of orbital cellulitis are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link&amp;anchor=H14#H14\">",
"     \"Orbital cellulitis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serious complications are very rare in preseptal cellulitis. It is rare for untreated preseptal cellulitis to give rise to orbital cellulitis and very rare for either infection to invade the globe (to produce endophthalmitis). However, some cases that are initially diagnosed as preseptal cellulitis may, in fact, be orbital cellulitis. Therefore, clinicians must be vigilant for features suggesting possible misdiagnosis. (See",
"    <a class=\"local\" href=\"#H83430777\">",
"     'Diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link&amp;anchor=H19539607#H19539607\">",
"     \"Orbital cellulitis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The tables indicate the clinical signs and symptoms associated with the two conditions (",
"    <a class=\"graphic graphic_table graphicRef55123 \" href=\"UTD.htm?28/42/29356\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef62818 \" href=\"UTD.htm?5/36/5711\">",
"     table 3",
"    </a>",
"    ). Combined with imaging studies, when indicated, these features usually allow for a reasonable degree of confidence in distinguishing between the two entities. However, the clinical evaluation can be challenging in young children, who may not be able to cooperate with a full examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H408229749\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of preseptal cellulitis includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Orbital cellulitis (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link\">",
"       \"Orbital cellulitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Insect bite",
"     </li>",
"     <li>",
"      Allergic response",
"     </li>",
"     <li>",
"      Hordeolum (stye)",
"     </li>",
"     <li>",
"      Conjunctivitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is critical to distinguish preseptal cellulitis from the more serious orbital cellulitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link&amp;anchor=H19539607#H19539607\">",
"     \"Orbital cellulitis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83430777\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of preseptal cellulitis is based upon the history (eg, insect bite, local face",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    eyelid trauma) and physical examination, but, in cases in which there is doubt, computed tomography (CT) scanning of the orbits and sinuses is used to distinguish preseptal cellulitis from orbital cellulitis. The approach to diagnosis when a case of preseptal cellulitis is difficult to distinguish from orbital cellulitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link&amp;anchor=H19539607#H19539607\">",
"     \"Orbital cellulitis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the low yield, we recommend obtaining blood cultures from patients with suspected preseptal cellulitis before the administration of antibiotics.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83430784\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrast-enhanced CT scanning of the orbits and sinuses is helpful for distinguishing between preseptal and orbital cellulitis. In preseptal cellulitis, there is swelling of the eyelid(s) but no proptosis, no fat stranding of the orbital contents, and no edema of the extraocular muscles. Sinusitis may be present in preseptal cellulitis, but is almost always present in orbital cellulitis. It is important to note that in some cases of orbital cellulitis, the CT scan abnormalities may be subtle.",
"   </p>",
"   <p>",
"    Imaging studies are indicated if any of the clinical signs or symptoms point to orbital cellulitis rather than preseptal cellulitis. They are also indicated in patients with presumed preseptal cellulitis who exhibit marked eyelid swelling, fever, and leukocytosis, or whose infection fails to show improvement after 24 to 48 hours of appropriate antibiotics. Imaging studies in patients with suspected orbital cellulitis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link&amp;anchor=H459379685#H459379685\">",
"     \"Orbital cellulitis\", section on 'Imaging studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83430791\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials of antibiotic regimens for the treatment of preseptal cellulitis. Blood cultures are rarely positive and cultures from the site of infection are difficult to obtain. Therefore, treatment is almost always empiric and based upon knowledge of the common infecting organisms (Staphylococcus aureus, Streptococcus pneumoniae, other streptococci and anaerobes) and their usual susceptibility patterns.",
"   </p>",
"   <p>",
"    Adults and children older than one year of age with mild preseptal cellulitis and no signs of systemic toxicity can generally be treated as outpatients with oral antibiotics provided that close follow-up can be ensured. Children younger than one year of age, children who cannot cooperate fully for an examination, and patients who are severely ill should generally be admitted to the hospital and managed according to the recommendations for orbital cellulitis. This is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link&amp;anchor=H24#H24\">",
"     \"Orbital cellulitis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to note that patients with subtle clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiographic findings suggesting that the orbit is involved should be treated as though they have orbital cellulitis given the serious complications of this entity. Young children who are not able to cooperate for a thorough examination should also be treated as though they have orbital cellulitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link&amp;anchor=H24#H24\">",
"     \"Orbital cellulitis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83430798\">",
"    <span class=\"h2\">",
"     Antibiotic regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of antibiotics for empiric treatment has been made much more difficult by the emergence of community-acquired methicillin-resistant S. aureus (CA-MRSA), which now constitute a substantial proportion of community-acquired strains of S. aureus. Previously,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    -clavulanic acid,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27333?source=see_link\">",
"     cefpodoxime",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/21/5461?source=see_link\">",
"     cefdinir",
"    </a>",
"    were excellent choices. However, these agents do not have activity against CA-MRSA. Orally administered drugs that have good activity against most strains of CA-MRSA include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , and tetracyclines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ). However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    -sulfamethoxazole and doxycycline are not reliably effective for group A streptococcal infections, and doxycycline is not approved for use in children under the age of eight years, and should be used with caution in such patients.",
"   </p>",
"   <p>",
"    Therefore, we suggest one of the following regimens for empiric oral treatment of preseptal cellulitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      (in children: 30 to 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in three to four equally divided doses, not to exceed 1.8 grams per day [",
"      <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/26\">",
"       26",
"      </a>",
"      ]; in adults: 300 mg every eight hours) monotherapy",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX; in children: 8 to 12",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      component divided every 12 hours; in adults: 8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day of the trimethoprim component divided every 8 or 12 hours [one double strength tablet contains 160 mg of trimethoprim; as examples, TMP-SMX can be given as one double strength tablet every 8 hours or two double strength tablets every 12 hours depending on the patient's weight])",
"      <strong>",
"       plus",
"      </strong>",
"      one of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       Amoxicillin",
"      </a>",
"      (in children: 80 to 100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in divided doses every eight hours; in adults: 875 mg orally every 12 hours)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       Amoxicillin",
"      </a>",
"      -clavulanic acid (in children: 45",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided every 12 hours; in adults: 875 mg every 12 hours)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27333?source=see_link\">",
"       Cefpodoxime",
"      </a>",
"      (in children: 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided every 12 hours, not to exceed 200 mg per dose; in adults: 400 mg every 12 hours)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/21/5461?source=see_link\">",
"       Cefdinir",
"      </a>",
"      (in children: 7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily, maximum daily dose 600 mg; in adults: 300 mg twice daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The recommendation to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    alone is based primarily on published susceptibility data rather than on clinical efficacy data for patients with preseptal cellulitis. However, the drug has shown good efficacy for skin and soft tissue infections caused by staphylococci and streptococci [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link&amp;anchor=H703095#H703095\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\", section on 'Clindamycin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=see_link\">",
"     \"Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient has not been immunized against Haemophilus influenzae, one of the combination regimens should be used in order to insure coverage for this organism.",
"   </p>",
"   <p>",
"    Topical antibiotics have no role in the treatment of this infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83430805\">",
"    <span class=\"h2\">",
"     Response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preseptal cellulitis typically responds rapidly and completely to appropriate antibiotics. Outpatients whose infections fail to show signs of improvement in 24 hours should generally be hospitalized, treated with broad-spectrum intravenous antibiotics, and undergo a computed tomography (CT) scan to evaluate for orbital cellulitis and its complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link&amp;anchor=H24#H24\">",
"     \"Orbital cellulitis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83430812\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no controlled trials evaluating the duration of antimicrobial therapy in preseptal cellulitis. Treatment recommendations are based on small case series. We generally recommend a duration of 7 to 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], but if signs of cellulitis persist at the end of this period, treatment should be continued until the eyelid erythema and swelling have resolved or nearly resolved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83430819\">",
"    <span class=\"h2\">",
"     Recurrent preseptal cellulitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preseptal cellulitis rarely recurs. When it does, it is usually due to an underlying cause that has not been diagnosed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. A case series of six patients with recurrent preseptal cellulitis, defined as three or more episodes within a one year period with complete resolution between episodes, identified the underlying cause in two patients as environmental allergies, and in one patient each as recurrent sinusitis, herpes simplex infection, contact dermatitis to cosmetics, and Munchausen&rsquo;s syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/29\">",
"     29",
"    </a>",
"    ]. An anatomic abnormality of the sinuses may also predispose to recurrent preseptal cellulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27751/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83431329\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preseptal cellulitis and orbital cellulitis involve different anatomic sites, with preseptal cellulitis referring to infections of the soft tissues anterior to the orbital septum and orbital cellulitis referring to infections posterior to it (",
"    <a class=\"graphic graphic_figure graphicRef68971 \" href=\"UTD.htm?18/7/18550\">",
"     figure 1",
"    </a>",
"    ). Orbital cellulitis involves the muscles and fat located within the orbit. Although preseptal and orbital cellulitis may be confused with one another because both can cause ocular pain and eyelid swelling and erythema, they have very different clinical implications. Preseptal cellulitis is generally a mild condition that rarely leads to serious complications, whereas orbital cellulitis may cause loss of vision and even loss of life. Orbital cellulitis can usually be distinguished from preseptal cellulitis by its clinical features (ophthalmoplegia, pain with eye movements, and proptosis) and by imaging studies; in cases in which the distinction is not clear, clinicians should treat patients as though they have orbital cellulitis. Both conditions are more common in children than in adults. (See",
"    <a class=\"local\" href=\"#H83430247\">",
"     'Introduction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H83430254\">",
"     'Terminology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preseptal cellulitis arises most commonly from sinusitis or a contiguous infection of the soft tissues of the face and eyelids secondary to local trauma, insect or animal bites, or foreign bodies. (See",
"      <a class=\"local\" href=\"#H83430756\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common causes of preseptal cellulitis are Streptococcus pneumoniae and other streptococci, Staphylococcus aureus (including community-acquired methicillin-resistant S. aureus [CA-MRSA]), and anaerobes (",
"      <a class=\"graphic graphic_table graphicRef77104 \" href=\"UTD.htm?35/15/36094\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H83430763\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of preseptal cellulitis is based upon the history (eg, insect bite, local face",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      eyelid trauma) and physical examination. However, in cases in which there is doubt, computed tomography (CT) scanning of the orbits and sinuses can usually distinguish preseptal cellulitis from orbital cellulitis. (See",
"      <a class=\"local\" href=\"#H83430777\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During the initial evaluation, it is critical to distinguish preseptal cellulitis from the more serious orbital cellulitis (",
"      <a class=\"graphic graphic_table graphicRef55123 \" href=\"UTD.htm?28/42/29356\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef62818 \" href=\"UTD.htm?5/36/5711\">",
"       table 3",
"      </a>",
"      ). Although both preseptal cellulitis and orbital cellulitis typically cause eyelid swelling and erythema, the presence of ophthalmoplegia, pain with eye movements, chemosis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      proptosis occur only with orbital cellulitis. (See",
"      <a class=\"local\" href=\"#H83430770\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adults and children older than one year of age with mild preseptal cellulitis can be managed on an outpatient basis, provided that the patient has no signs of systemic toxicity and close follow-up is ensured. In these cases, we recommend treatment with oral antibiotics with activity against S. aureus (including MRSA) and streptococci, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      monotherapy or combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      <strong>",
"       plus",
"      </strong>",
"      one of the following agents:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      , amoxicillin-clavulanic acid,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27333?source=see_link\">",
"       cefpodoxime",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/21/5461?source=see_link\">",
"       cefdinir",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). If the patient has not been immunized against Haemophilus influenzae, one of the combination regimens should be used. (See",
"      <a class=\"local\" href=\"#H83430798\">",
"       'Antibiotic regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We generally recommend a treatment duration of 7 to 10 days, but if signs of cellulitis persist at the end of this period, treatment should be continued until the erythema and swelling have resolved or nearly resolved. (See",
"      <a class=\"local\" href=\"#H83430812\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients younger than one year of age and those who are severely ill should be admitted to the hospital and managed according to the recommendations for orbital cellulitis. Patients with subtle clinical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiographic findings suggesting that the orbit is involved, as well as young children who are not able to cooperate for a thorough examination, should also be treated as though they have orbital cellulitis given the serious complications of this entity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link&amp;anchor=H24#H24\">",
"       \"Orbital cellulitis\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/1\">",
"      Zhang J, Stringer MD. Ophthalmic and facial veins are not valveless. Clin Experiment Ophthalmol 2010; 38:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/2\">",
"      Ambati BK, Ambati J, Azar N, et al. Periorbital and orbital cellulitis before and after the advent of Haemophilus influenzae type B vaccination. Ophthalmology 2000; 107:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/3\">",
"      Botting AM, McIntosh D, Mahadevan M. Paediatric pre- and post-septal peri-orbital infections are different diseases. A retrospective review of 262 cases. Int J Pediatr Otorhinolaryngol 2008; 72:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/4\">",
"      Mills RP, Kartush JM. Orbital wall thickness and the spread of infection from the paranasal sinuses. Clin Otolaryngol Allied Sci 1985; 10:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/5\">",
"      Jackson K, Baker SR. Periorbital cellulitis. Head Neck Surg 1987; 9:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/6\">",
"      Ganesh A, Venugopalan P. Preseptal orbital cellulitis following oral trauma. J Pediatr Ophthalmol Strabismus 2000; 37:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/7\">",
"      Smith TF, O'Day D, Wright PF. Clinical implications of preseptal (periorbital) cellulitis in childhood. Pediatrics 1978; 62:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/8\">",
"      Hutcheson KA, Magbalon M. Periocular abscess and cellulitis from Pasteurella multocida in a healthy child. Am J Ophthalmol 1999; 128:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/9\">",
"      Chaudhry IA, Shamsi FA, Elzaridi E, et al. Inpatient preseptal cellulitis: experience from a tertiary eye care centre. Br J Ophthalmol 2008; 92:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/10\">",
"      Charalampidou S, Connell P, Fennell J, et al. Preseptal cellulitis caused by community acquired methicillin resistant Staphylococcus aureus (CAMRSA). Br J Ophthalmol 2007; 91:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/11\">",
"      Blomquist PH. Methicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2006; 104:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/12\">",
"      Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/13\">",
"      Miller J. Acinetobacter as a causative agent in preseptal cellulitis. Optometry 2005; 76:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/14\">",
"      Mathews D, Mathews JP, Kwartz J, Inkster C. Preseptal cellulitis caused by Acinetobacter lwoffi. Indian J Ophthalmol 2005; 53:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/15\">",
"      Brannan PA, Kersten RC, Hudak DT, et al. Primary Nocardia brasiliensis of the eyelid. Am J Ophthalmol 2004; 138:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/16\">",
"      Ca&ccedil;a I, Cakmak SS, Unl&uuml; K, et al. Cutaneous anthrax on eyelids. Jpn J Ophthalmol 2004; 48:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/17\">",
"      Milstone AM, Ruff AJ, Yeamans C, Higman MA. Pseudomonas aeruginosa pre-septal cellulitis and bacteremia in a pediatric oncology patient. Pediatr Blood Cancer 2005; 45:353; discussion 354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/18\">",
"      Raja NS, Singh NN. Bilateral orbital cellulitis due to Neisseria gonorrhoeae and Staphylococcus aureus: a previously unreported case. J Med Microbiol 2005; 54:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/19\">",
"      Sears JM, Gabriel HM, Veith J. Preseptal cellulitis secondary to Proteus species: a case report and review. J Am Optom Assoc 1999; 70:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/20\">",
"      Raina UK, Jain S, Monga S, et al. Tubercular preseptal cellulitis in children: a presenting feature of underlying systemic tuberculosis. Ophthalmology 2004; 111:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/21\">",
"      Velazquez AJ, Goldstein MH, Driebe WT. Preseptal cellulitis caused by trichophyton (ringworm). Cornea 2002; 21:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/22\">",
"      Seltz LB, Smith J, Durairaj VD, et al. Microbiology and antibiotic management of orbital cellulitis. Pediatrics 2011; 127:e566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/23\">",
"      Nageswaran S, Woods CR, Benjamin DK Jr, et al. Orbital cellulitis in children. Pediatr Infect Dis J 2006; 25:695.",
"     </a>",
"    </li>",
"    <li>",
"     Durand, ML. Periocular infections. In: Principles and Practice of Infectious Diseases, 7th ed, Mandell, GL, Bennett, et al.  (Eds), Churchill Livingstone Elsevier, Philadelphia 2010. p.1569.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/25\">",
"      Sobol SE, Marchand J, Tewfik TL, et al. Orbital complications of sinusitis in children. J Otolaryngol 2002; 31:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/26\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/27\">",
"      Howe L, Jones NS. Guidelines for the management of periorbital cellulitis/abscess. Clin Otolaryngol Allied Sci 2004; 29:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/28\">",
"      Uzc&aacute;tegui N, Warman R, Smith A, Howard CW. Clinical practice guidelines for the management of orbital cellulitis. J Pediatr Ophthalmol Strabismus 1998; 35:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/29\">",
"      Sorin A, April MM, Ward RF. Recurrent periorbital cellulitis: an unusual clinical entity. Otolaryngol Head Neck Surg 2006; 134:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27751/abstract/30\">",
"      Karkos PD, Karagama Y, Karkanevatos A, Srinivasan V. Recurrent periorbital cellulitis in a child. A random event or an underlying anatomical abnormality? Int J Pediatr Otorhinolaryngol 2004; 68:1529.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16650 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-F7344C3B4D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_6_27751=[""].join("\n");
var outline_f27_6_27751=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H83431329\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83430247\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83430254\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83430261\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H234333111\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83430756\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83430763\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83430770\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H408229749\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83430777\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83430784\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83430791\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83430798\">",
"      Antibiotic regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83430805\">",
"      Response to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83430812\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83430819\">",
"      Recurrent preseptal cellulitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83431329\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/16650\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16650|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/7/18550\" title=\"figure 1\">",
"      The orbital septum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/4/20547\" title=\"figure 2\">",
"      Exposed medial wall of orbit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/51/821\" title=\"figure 3\">",
"      Orbital venous drainage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16650|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/28/9670\" title=\"picture 1\">",
"      Orbital cellulitis photo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16650|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/15/36094\" title=\"table 1\">",
"      Microbiology of preseptal and orbital cellulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/42/29356\" title=\"table 2\">",
"      Clinical features of preseptal and orbital cellulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/36/5711\" title=\"table 3\">",
"      Preseptal and orbital cellulitis studies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=related_link\">",
"      Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41608?source=related_link\">",
"      Microbiology, epidemiology and treatment of Haemophilus influenzae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=related_link\">",
"      Orbital cellulitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5767?source=related_link\">",
"      Tuberculosis and the eye",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_6_27752="General principles of dermatologic therapy and topical corticosteroid use";
var content_f27_6_27752=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   General principles of dermatologic therapy and topical corticosteroid use",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/6/27752/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/6/27752/contributors\">",
"     Beth G Goldstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/6/27752/contributors\">",
"     Adam O Goldstein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/6/27752/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/6/27752/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/6/27752/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/6/27752/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/6/27752/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/6/27752/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 14, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The success of dermatologic therapies is dependent upon many factors. General issues related to topical therapies will be reviewed here with a particular emphasis upon the use of topical corticosteroids.",
"   </p>",
"   <p>",
"    There are five components to the successful use of topical therapies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Correct diagnosis",
"     </li>",
"     <li>",
"      Type of lesion being treated",
"     </li>",
"     <li>",
"      Medication",
"     </li>",
"     <li>",
"      Vehicle (the base in which the active medication is delivered)",
"     </li>",
"     <li>",
"      Method used to apply the medication",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The type of lesion being treated is important. In acute contact dermatitis from poison ivy with moist weeping lesions, wet dressing changes or lotions will help \"dry up\" the dermatitis while providing cool, soothing relief. Thus, for acute exudative dermatoses, bland treatments in liquid vehicles (eg, lotions) are generally recommended. In contrast, when treating chronic psoriasis, therapeutic agents incorporated into creams or ointments may help to retain native moisture and provide relief to dry, pruritic skin.",
"   </p>",
"   <p>",
"    Topical corticosteroids are available in a variety of vehicles. If the correct medication but the wrong vehicle is used, the response to therapy may be delayed, inadequate, or in some cases, worsened. As examples, use of a corticosteroid gel on hand eczema and fissures will cause increased pain and stinging due to the alcohol base of the gel. Treating a moist lesion with an ointment may cause folliculitis secondary to its occlusive properties.",
"   </p>",
"   <p>",
"    In addition to the type of lesion being treated and the base of the treatment vehicle, topical drug penetration into the skin is determined by the method of topical application. For optimal absorption of most topical drugs, apply them to moist skin either immediately after bathing or after wet soaks. Occlusive dressings will also enhance drug absorption, often by a factor of 10. The site of an application is also important as variations in the epidermal layer will alter the extent of drug absorption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VEHICLE SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vehicles consist of three basic ingredients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Powders",
"     </li>",
"     <li>",
"      Oils",
"     </li>",
"     <li>",
"      Liquids (eg, water)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Powders absorb moisture, decrease friction, and help cover wide areas easily. Oils act as emollients and, because of their occlusive properties, often enhance drug penetration. Liquids in vehicles evaporate, providing a cooling, soothing sensation, while aiding exudative lesions to dry. Combinations of these three ingredients in varying proportions make up the most commonly used vehicles, which are described below. The optimal vehicles for different body locations and lesions are shown in a table (",
"    <a class=\"graphic graphic_table graphicRef60921 \" href=\"UTD.htm?5/11/5308\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ointments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ointments consist predominantly of water suspended in oil. This type of vehicle is an excellent lubricant, facilitates heat retention, decreases transepidermal water loss, provides enhanced medication absorption, and is semiocclusive. Ointments are generally the most potent vehicles due to their occlusive effect, but patient acceptance may be low because they are greasy, and they are not useful in hairy areas. Ointments should be applied two to three times per day to dry, lichenified lesions, particularly after moistening the skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Creams",
"    </span>",
"    &nbsp;&mdash;&nbsp;Creams are semisolid emulsions of oil in 20 to 50 percent water and can be washed off with water. They are cosmetically appealing vehicles for delivering topical medications. For the same medication, cream formulations are usually stronger than lotions, but less potent than ointments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lotions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lotions (as well as aerosols and solutions) are the least potent topical therapies, but are useful in hairy areas and in conditions where large areas have to be treated. They consist of powder-in-water; thus, patients must shake the container before each application to receive the desired therapeutic concentration (and therefore the desired effect). In addition, as lotions evaporate, they provide a cooling and drying effect, making them useful for treating moist dermatoses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pruritus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Solutions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solutions contain water or non-aqueous liquids such as alcohol or propylene glycol. Solutions such as bath soaks and open wet dressings provide coolness and aid in drying exudative lesions by means of evaporation. In addition, vasoconstriction results in decreased local blood flow and reduction in local edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Wet dressings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wet dressings permit the cleansing of exudate while maintaining drainage in infected lesions (eg, ulcers). Wet dressings should be changed every six hours for two to three days before judging their effectiveness. Closed wet dressings consist of a wet dressing covered by an impermeable substance such as a polyurethane plastic (eg, Saran Wrap), which allows heat to be retained, prevents evaporation, and causes maceration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gels are an oil-in-water emulsion with alcohol in the base, and they dry in a thin, greaseless, nonstaining film. Gel formulations combine the best therapeutic advantages of ointments with the best cosmetic advantages of creams. Gels are transparent, colorless, semisolid emulsions that liquefy on contact with the skin. They are an efficient method for delivering medications to hair-bearing areas and for treating acne.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Foams",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foams are pressurized collections of gaseous bubbles in a matrix of liquid film. Foam preparations spread readily and are easier to apply than other preparations, particularly for inflamed skin and for scalp dermatoses. They are also often more cosmetically acceptable, which can lead to higher compliance.",
"   </p>",
"   <p>",
"    Unlike other vehicles, foams depend on the vehicle delivery system for the physical delivery of the drug. Because of the complexities in designing vehicle delivery systems, foam preparations tend to be more expensive than other vehicles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TOPICAL CORTICOSTEROIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical corticosteroids induce an antiinflammatory response in the skin by a variety of mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. They also appear to have antimitotic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/1\">",
"     1",
"    </a>",
"    ]; this finding may help explain their utility in the treatment of scaling dermatoses, and may relate to the occurrence of dermal thinning due to fibroblast inhibition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Potency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical corticosteroids induce cutaneous vasoconstriction commensurate with their potency. The standard vasoconstriction bioassay provides potency measurements that correlate well with clinical antiinflammatory efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical corticosteroids can be subdivided into four groups (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Super high potency (Class I)",
"     </li>",
"     <li>",
"      High potency (Classes II to III)",
"     </li>",
"     <li>",
"      Medium potency (Classes IV to V)",
"     </li>",
"     <li>",
"      Low potency (Classes VI to VII)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A Class I agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    propionate ointment) is approximately 1000 times more potent than 1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Corticosteroids are better absorbed through areas of inflammation and desquamation than normal skin, and more readily through the thin stratum corneum of infants than the skin of adults [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/4\">",
"     4",
"    </a>",
"    ]. Furthermore, anatomic regions with a thin epidermis are significantly more permeable to topical steroids than thick-skinned areas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/5\">",
"     5",
"    </a>",
"    ]. Regional differences in percutaneous absorption (percent of the total dose absorbed across the body) are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sole of foot &mdash; 0.14 percent",
"     </li>",
"     <li>",
"      Palm &mdash; 0.83 percent",
"     </li>",
"     <li>",
"      Forearm &mdash; 1.0 percent",
"     </li>",
"     <li>",
"      Scalp &mdash; 3.5 percent",
"     </li>",
"     <li>",
"      Forehead &mdash; 6.0 percent",
"     </li>",
"     <li>",
"      Mandible &mdash; 13 percent",
"     </li>",
"     <li>",
"      Genitalia &mdash; 42 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other factors that affect topical corticosteroid potency include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increases in concentration of a particular corticosteroid within a finite range in a defined vehicle enhance potency [",
"      <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Occlusive dressings promote cutaneous hydration and significantly increase absorption and potency. Occlusion can enhance topical corticosteroid potency by as much as 100-fold.",
"     </li>",
"     <li>",
"      Ointment preparations generally allow better percutaneous drug absorption and are therefore more potent than creams and lotions. One exception is the super-potent topical corticosteroid (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      dipropionate) that may be packaged in \"optimized\" cream vehicles (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Corticosteroid selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The corticosteroid selection depends, to some extent, upon the condition being treated. In general, is best to start with the lowest potency agents needed and use for as short a period of time as possible. Some general recommendations regarding selection of the optimal corticosteroid preparation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Super high potency corticosteroids are used for severe dermatoses over",
"      <span class=\"nowrap\">",
"       nonfacial/nonintertriginous",
"      </span>",
"      areas (eg, psoriasis, severe atopic dermatitis, severe contact dermatitis). They are especially useful over the palms and soles, which tend to resist topical corticosteroid penetration due to the thick stratum corneum.",
"     </li>",
"     <li>",
"      Medium to high potency strength preparations are appropriate for mild to moderate",
"      <span class=\"nowrap\">",
"       nonfacial/nonintertriginous",
"      </span>",
"      dermatoses.",
"     </li>",
"     <li>",
"      Eyelid and genital dermatoses should be managed with low potency topical corticosteroids.",
"     </li>",
"     <li>",
"      Low to medium strength preparations should be considered when large areas are treated because of the likelihood of systemic absorption.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Generic topical corticosteroids are effective for treating the majority of skin disorders seen in the primary care setting. Generic medications often have slightly less potency or less cosmetically appealing vehicles [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/7\">",
"     7",
"    </a>",
"    ], but the often substantial cost savings may negate any differences in efficacy or feel.",
"   </p>",
"   <p>",
"    Penetration and efficacy are optimized when topical corticosteroids are applied to moist skin after bathing or soaking in water. However, they may also be applied to dry skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treatment duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of daily use of super high potency topical corticosteroids should not exceed three weeks if possible, although persistent lesions on small areas may be treated for a longer time [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/8\">",
"     8",
"    </a>",
"    ]. High potency and medium strength preparations rarely cause cutaneous side effects if used for less than six to eight weeks, although they can occur with shorter courses of treatment, especially on the face and intertriginous areas.",
"   </p>",
"   <p>",
"    For some disorders, intermittent therapy may be effective for maintaining long-term disease control. In randomized trials, twice weekly application of topical corticosteroids has been shown to reduce the risk of relapse in patients with atopic dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Corticosteroids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Side effects are rare with low potency topical corticosteroids; nevertheless, intermittent therapy may be preferable to continuous therapy for the long-term treatment of large skin areas. Facial, intertriginous, and genital dermatoses should be treated for short one to two week intervals since these areas are most susceptible to corticosteroid-induced atrophy, telangiectasia, and acneiform eruption (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Cutaneous'",
"    </a>",
"    below). Application to highly permeable areas also increases systemic absorption and is another reason to limit the duration of treatment in these areas (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Systemic'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Topical corticosteroids should be discontinued when the skin condition has resolved. Rebound of the skin condition being treated can be avoided by tapering topical therapy with a gradual reduction of both potency and dosing frequency at two-week intervals.",
"   </p>",
"   <p>",
"    Longer courses of therapy may be necessary for patients with chronic diseases, and these individuals should be closely monitored for the development of adverse effects. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Use in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of lower potency (classes IV to VII) topical corticosteroids in children is generally safe when used for short durations and for appropriate inflammatory conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/11\">",
"     11",
"    </a>",
"    ]. Children under age 12 years typically should not use potent or super potent topical corticosteroids. An exception can be made for very severe inflammatory dermatoses (eg, psoriasis, severe atopic dermatitis), for which short courses (up to two weeks) of more potent (classes I to III) topical corticosteroids may be warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of psoriasis\", section on 'Corticosteroids'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Corticosteroids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To minimize the risk of side effects, high potency corticosteroids (including combination",
"    <span class=\"nowrap\">",
"     antifungal/topical",
"    </span>",
"    corticosteroid products) should not be used on the face, intertriginous, or other thin-skinned highly penetrable areas (eg, the perineum, axillae) in children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. In addition, high potency corticosteroids ideally should be used only once a day and should not be administered for longer than two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/16\">",
"     16",
"    </a>",
"    ]. Even low potency topical corticosteroids can cause side effects in children when used for extended periods of time. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Side effects'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H24\">",
"     'Combination antifungal/topical corticosteroid products'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Children usually require significantly less topical corticosteroids for a given condition than do adults because children have a smaller body surface area. Based upon calculation of mean body surface area, one guideline for topical corticosteroids quantities suggests that infants be given one-fifth of the adult dose, children be given two-fifths of the adult dose, and adolescents be given two-thirds of adult doses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Use during pregnancy or lactation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limited available data on the safety of topical corticosteroids in pregnancy is composed primarily of observational studies with methodological flaws [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/18\">",
"     18",
"    </a>",
"    ]. An increased risk for orofacial cleft was reported with topical corticosteroid use in one case control study of 106 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/19\">",
"     19",
"    </a>",
"    ], and a cohort study of 99 women reported a correlation between low birth weight and high potency topical corticosteroid use during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/20\">",
"     20",
"    </a>",
"    ]. However, a systematic review found no conclusive evidence supporting an association between maternal use of topical corticosteroids during pregnancy and congenital anomalies, preterm delivery, or stillbirth [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/18\">",
"     18",
"    </a>",
"    ]. Additional studies are necessary to investigate the safety of topical corticosteroid use during pregnancy.",
"   </p>",
"   <p>",
"    It is not known whether these drugs are secreted in breast milk; no adverse effects have been noted in lactating women. The drugs should not be applied to the nipples prior to nursing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical corticosteroids are safer than systemic glucocorticoids. Nevertheless, cutaneous and systemic side effects can occur, particularly with super potent and potent drugs, or extensive use of lower potency agents with or without occlusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Cutaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of cutaneous effects may occur with topical corticosteroid use:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Super potent and potent topical corticosteroids may induce atrophy, telangiectasia, and striae as early as two to three weeks following daily application [",
"      <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/21\">",
"       21",
"      </a>",
"      ]. Intertriginous and thin-skinned highly penetrable areas are particularly susceptible to atrophy, which usually recovers within weeks to months if therapy is discontinued as soon as atrophic change occurs. A small study of 20 patients with psoriasis found that limited use (to skin lesions less than 2x2 cm) of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      propionate ointment (a class III agent) for ten weeks on the face and intertriginous areas did not cause atrophy or telangiectasia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prolonged use of topical steroids may induce an acneiform eruption that resolves with discontinuance of corticosteroids treatment. Chronic application of topical steroids to the face also may cause a dry, scaly eruption with scattered follicular pustules around the mouth (perioral dermatitis), and use of potent topical corticosteroids on the face can cause a facial eruption that is indistinguishable from rosacea [",
"      <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link\">",
"       \"Rosacea: Pathogenesis, clinical features, and diagnosis\"",
"      </a>",
"      .) Treatment includes discontinuation of steroid therapy with a gradual taper.",
"     </li>",
"     <li>",
"      Other cutaneous side effects of topical corticosteroids include purpura, changes in pigmentation, and hypertrichosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Allergic sensitization to topical corticosteroid preparations can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/25\">",
"     25",
"    </a>",
"    ]. Vehicles or preservatives most often are the sensitizing agents, although contact allergy against the steroid moiety itself is possible [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Topical glucocorticoid-induced contact allergy should be suspected in patients with chronic dermatoses that appear to be exacerbated by therapy. Patch testing is useful for determining whether contact dermatitis associated with a topical corticosteroid is secondary to the vehicle or to the corticosteroid itself [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/27\">",
"     27",
"    </a>",
"    ]. Cross-reactions between different topical corticosteroids are determined by their chemical structure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/28\">",
"     28",
"    </a>",
"    ]. The classification of topical corticosteroids (Class A through D) by pattern of cross-reactivity is illustrated in the table (",
"    <a class=\"graphic graphic_figure graphicRef63402 \" href=\"UTD.htm?10/52/11075\">",
"     figure 1",
"    </a>",
"    ). Cross reactivity between groups is not uncommon. Class C topical corticosteroids have the lowest rate of allergenicity. Referral for patch testing may be indicated in patients whose history and examination are suggestive of a contact dermatitis to topical corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Systemic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical corticosteroids, particularly class I agents (the strongest), can cause significant hypothalamic pituitary axis (HPA) suppression using as little as 2",
"    <span class=\"nowrap\">",
"     grams/day",
"    </span>",
"    for two or more weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In one report, temporary reversible suppression was noted in 8 of 40 patients (20 percent) with psoriasis treated with super potent topical corticosteroids for three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/31\">",
"     31",
"    </a>",
"    ]. Factors that predispose to HPA suppression include use of high potency corticosteroids, chronic use, application to highly permeable areas, treatment of large areas, occlusion, poor skin integrity, liver failure, and young age. Routine use of even mild corticosteroids in young children can cause HPA axis suppression. Systemic absorption is increased when there is an altered skin barrier, which is common in the conditions for which these medications are prescribed.",
"   </p>",
"   <p>",
"    Hyperglycemia and unmasking of latent diabetes mellitus can also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, chronic periorbital application of topical corticosteroids may induce posterior subcapsular cataracts [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical corticosteroids can also worsen and alter the appearance of tinea skin infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link\">",
"     \"Dermatophyte (tinea) infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1591664\">",
"    <span class=\"h2\">",
"     Tachyphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tachyphylaxis, a progressive decrease in clinical response due to repetitive use of a drug, occurs when the body becomes tolerant to the pharmacotherapeutic effects of a particular medication. Even if the medication previously worked well, it may become ineffective. Allowing for drug-free intervals or switching to alterative agents may alleviate tachyphylaxis.",
"   </p>",
"   <p>",
"    Tachyphylaxis has been associated with topical corticosteroid use based upon experimental data showing reductions in corticosteroid-induced vasoconstriction, anti-proliferative effects, and inhibition of histamine release following repeated applications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. However, some authors have challenged that this data may not be broadly applicable to clinical use [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In one study of 32 patients with psoriasis that specifically assessed for tachyphylaxis, no evidence for this phenomenon was observed during daily treatment with a high potency topical corticosteroid for three months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/36\">",
"     36",
"    </a>",
"    ]. In the clinical setting, decreased patient adherence to treatment regimens over time is another factor that may account for apparent reductions in corticosteroid efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     INTRALESIONAL CORTICOSTEROID",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intralesional corticosteroids, in a variety of concentrations, are used to treat keloids, hemangiomas, acne cysts, stubborn psoriatic plaques, and alopecia areata.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     Triamcinolone",
"    </a>",
"    acetonide (2.5 to 60",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    triamcinolone diacetate (5 to 40 mg),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    sodium succinate (10 to 40",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    and methylprednisolone acetate (40 to 120",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    are used commonly. Adverse effects include local reactions and systemic absorption with problems similar to that of systemic corticosteroids. In addition, localized atrophy, hypopigmentation, telangiectasia, and sterile abscesses may occur related to intralesional injections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=see_link\">",
"     \"Intralesional injection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PITFALLS OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assuming that a proper diagnosis is made, the most common treatment errors are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suboptimal medication use related to either too low or too high medication strength, improper vehicle, or insufficient dosage",
"     </li>",
"     <li>",
"      Lack of patient adherence as a result of inadequate patient education or adverse drug events",
"     </li>",
"     <li>",
"      The use of combination",
"      <span class=\"nowrap\">",
"       steroid/antifungal",
"      </span>",
"      formulations",
"     </li>",
"     <li>",
"      Drug interactions",
"     </li>",
"     <li>",
"      Disregard for medication costs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first three issues are discussed in more detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Suboptimal medication use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent example of suboptimal medication use is the patient with extensive or facial contact dermatitis who is given a five to seven day",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    dose pack (ie, a tapering dose over five to seven days) along with a 30 gram tube of 1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    cream. The patient does well for two or three days at the highest dosage of prednisolone, but new lesions continue to develop. A better treatment regimen involves using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    as the oral glucocorticoid, given in high enough dosage (eg, 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of ideal body weight) for a long enough time to cover the seven to ten days of lesion outbreak (eg, 50 mg; decrease by 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    over 10 days). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link\">",
"     \"Overview of dermatitis\"",
"    </a>",
"    .) In addition, the hydrocortisone cream is not strong enough to treat most cases of moderate inflammation, and the quantity prescribed is sufficient to cover the involved areas for only three days.",
"   </p>",
"   <p>",
"    Other common examples include selecting the incorrect fungal agent for a documented fungal infection (eg, using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    for a dermatophyte infection when the drug is active only against Candida), or using topical antifungal agents for tinea capitis when oral therapy is the correct route of administration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link\">",
"     \"Dermatophyte (tinea) infections\"",
"    </a>",
"    .) Another problem is using a medication for too short a time period to effectively treat the condition (eg, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/61/6102?source=see_link\">",
"     griseofulvin",
"    </a>",
"    for tinea capitis for less than a month, as it must be used for a minimum of at least two to three months).",
"   </p>",
"   <p>",
"    When prescribing a medication, the amount to be dispensed needs to be considered carefully. An insufficient amount of medication used by the patient will lead most often to an inadequate therapeutic response. When considering the amount used per application, the number of applications to be given daily, and the duration of therapy, the prescription can be written so the patient will not run out of medication prematurely (",
"    <a class=\"graphic graphic_table graphicRef76586 \" href=\"UTD.htm?30/19/31035\">",
"     table 3",
"    </a>",
"    ). The Fingertip Unit (FTU) is a convenient method to estimate the amount of a topical preparation to be used per application [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/38\">",
"     38",
"    </a>",
"    ]. Each FTU is approximately equivalent to 0.5 and 0.4 grams of ointment in men and women, respectively. An estimate of the number of FTUs required to cover various areas of the body is as follows: head and neck = 4.5, trunk (front or back) = 7, one arm = 3, one hand = 1, one leg = 6, and one foot = 2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Patient compliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper patient adherence to the prescribed treatment includes receiving thorough patient education about the nature of the problem and proper use of the medication. As an example, one of the most difficult conditions to successfully manage is urticaria. Patients are miserable, and the unpredictable nature of the outbreaks requires that the physician provide extra emotional support. Patients expect the urticaria to resolve while medications are taken \"as necessary.\" If the patient understands that taking antihistamines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/25/19862?source=see_link\">",
"     cyproheptadine",
"    </a>",
"    ) \"around the clock\" is an essential aspect in management, both the physician and patient are more likely to be satisfied with the outcome.",
"   </p>",
"   <p>",
"    Patients with chronic conditions such as acne or atopic dermatitis must be educated about the natural history of exacerbations and remissions, as well as the time needed to see any improvement after initiating the designated pharmacotherapy. Otherwise, patients may relate that the medication was working, but the desired effect did not persist after discontinuing its use. Clinicians also may hear from a teenager's parent, calling to state that the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    prescribed two weeks ago is making the child's acne worse. As tetracycline may not show any beneficial effects for six to eight weeks, it is helpful to explain the natural course of acne and arrive at mutual, realistic expectations.",
"   </p>",
"   <p>",
"    If the skin condition is not responding, remember that the diagnosis and treatment may be correct, but the patient may not be following your recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/39\">",
"     39",
"    </a>",
"    ]. Ask patients to bring all of their medications (both prescription and over-the-counter) with them to every office visit. Are the tubes of cream still full? Are there as many pills used as expected? Are there other reasons for not complying with medication use, such as cost or adverse drug effects?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Combination antifungal/topical corticosteroid products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many clinicians will prescribe a combination",
"    <span class=\"nowrap\">",
"     antifungal/topical",
"    </span>",
"    steroid product (eg, Mycolog, Lotrisone) to a patient with a skin lesion because they are unsure if the diagnosis is fungal or inflammatory dermatitis. Usually a simple KOH scraping can differentiate the two conditions enabling the clinician to prescribe one rather than two medications. Two problems with these combination products are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They are expensive compared to generic topical steroid and over the counter topical antifungal products alone. In one study, nondermatologists were more likely than dermatologists to prescribe combination",
"      <span class=\"nowrap\">",
"       antifungal/topical",
"      </span>",
"      steroid products for the treatment of common fungal skin infections (34 versus 5 percent), costing an addition $10 to 25 million dollars as a whole to the health care system [",
"      <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The steroid preparation in the combination products is potent. If patients are using the potent steroid on a simple fungal infection, they risk incomplete resolution of the fungal infection as well as thinning of the skin if used for a prolonged period of time [",
"      <a class=\"abstract\" href=\"UTD.htm?27/6/27752/abstract/41,42\">",
"       41,42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1591875\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Topical medications are commonly used for the treatment of skin disorders. Lesion type and location are important factors for determining the most appropriate regimen for therapy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Topical medications are available in a variety of vehicles, including ointments, creams, lotions, solutions, gels, and foams. Factors such as lesion quality (eg, moist versus dry) and location (eg, hairy versus nonhairy skin) play an important role in vehicle selection. Care should be taken to select the most appropriate vehicle. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Vehicle selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Topical corticosteroids are classified into seven groups according to potency. The potency of a drug is influenced by the vehicle. In the clinical setting, the use of occlusion can increase the potency of topical corticosteroids. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Potency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cutaneous atrophy is a potential side effect of topical corticosteroid therapy, and is more likely to occur with the use of higher potency agents. In general, the use of super high potency topical corticosteroids should be restricted to highly inflammatory dermatoses on the scalp, trunk, or extremities. Facial or intertriginous areas are most likely to develop signs of cutaneous atrophy. Lesions in these areas should be treated with low potency corticosteroids. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Topical corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment with topical corticosteroids should be restricted to the shortest duration of therapy required to achieve the desired effect. Acneiform eruptions, purpura, hypopigmentation, glaucoma, and suppression of the hypothalamic-pituitary axis are additional side effects that may occur with topical corticosteroid use. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Topical corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Suboptimal medication use due to improper prescribing or poor communication with patients can result in treatment failure. When prescribing topical medications, care should be taken to ensure that the quantity prescribed is sufficient to cover the entire treatment area for the duration of treatment. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Pitfalls of treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/1\">",
"      Miller JA, Munro DD. Topical corticosteroids: clinical pharmacology and therapeutic use. Drugs 1980; 19:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/2\">",
"      Chan HL. The effects of topical corticosteroids on human skin. Ann Acad Med Singapore 1991; 20:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/3\">",
"      Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol 1985; 121:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/4\">",
"      Feiwel M, James VH, Barnett ES. Effect of potent topical steroids on plasma-cortisol levels of infants and children with eczema. Lancet 1969; 1:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/5\">",
"      McKensie, AW, Stoughton, RB. Method for comparing cutaneous absorption of steroids. Arch Dermatol 1962; 86:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/6\">",
"      Stoughton RB, Wullich K. The same glucocorticoid in brand-name products. Does increasing the concentration result in greater topical biologic activity? Arch Dermatol 1989; 125:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/7\">",
"      Olsen EA. A double-blind controlled comparison of generic and trade-name topical steroids using the vasoconstriction assay. Arch Dermatol 1991; 127:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/8\">",
"      Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for the use of topical glucocorticosteroids. American Academy of Dermatology. J Am Acad Dermatol 1996; 35:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/9\">",
"      Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002; 147:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/10\">",
"      Glazenburg EJ, Wolkerstorfer A, Gerretsen AL, et al. Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls? Pediatr Allergy Immunol 2009; 20:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/11\">",
"      Hebert AA, Friedlander SF, Allen DB. Topical fluticasone propionate lotion does not cause HPA axis suppression. J Pediatr 2006; 149:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/12\">",
"      Resnick SD, Hornung R, Konrad TR. A comparison of dermatologists and generalists. Management of childhood atopic dermatitis. Arch Dermatol 1996; 132:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/13\">",
"      Balkrishnan R, Camacho FT, Pearce DJ, et al. Factors affecting prescription of ultra-high potency topical corticosteroids in skin disease: an analysis of US national practice data. J Drugs Dermatol 2005; 4:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/14\">",
"      Ozon A, Cetinkaya S, Alikasifoglu A, et al. Inappropriate use of potent topical glucocorticoids in infants. J Pediatr Endocrinol Metab 2007; 20:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/15\">",
"      Semiz S, Balci YI, Ergin S, et al. Two cases of Cushing's syndrome due to overuse of topical steroid in the diaper area. Pediatr Dermatol 2008; 25:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/16\">",
"      Schlessinger J, Miller B, Gilbert RD, et al. An open-label adrenal suppression study of 0.1% fluocinonide cream in pediatric patients with atopic dermatitis. Arch Dermatol 2006; 142:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/17\">",
"      Nelson AA, Miller AD, Fleischer AB, et al. How much of a topical agent should be prescribed for children of different sizes? J Dermatolog Treat 2006; 17:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/18\">",
"      Chi CC, Wang SH, Kirtschig G, Wojnarowska F. Systematic review of the safety of topical corticosteroids in pregnancy. J Am Acad Dermatol 2010; 62:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/19\">",
"      Edwards MJ, Agho K, Attia J, et al. Case-control study of cleft lip or palate after maternal use of topical corticosteroids during pregnancy. Am J Med Genet A 2003; 120A:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/20\">",
"      Mah&eacute; A, Perret JL, Ly F, et al. The cosmetic use of skin-lightening products during pregnancy in Dakar, Senegal: a common and potentially hazardous practice. Trans R Soc Trop Med Hyg 2007; 101:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/21\">",
"      Katz HI, Prawer SE, Mooney JJ, Samson CR. Preatrophy: covert sign of thinned skin. J Am Acad Dermatol 1989; 20:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/22\">",
"      Lebwohl MG, Tan MH, Meador SL, Singer G. Limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol 2001; 44:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/23\">",
"      Litt JZ. Steroid-induced rosacea. Am Fam Physician 1993; 48:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/24\">",
"      Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/25\">",
"      Davis MD, el-Azhary RA, Farmer SA. Results of patch testing to a corticosteroid series: a retrospective review of 1188 patients during 6 years at Mayo Clinic. J Am Acad Dermatol 2007; 56:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/26\">",
"      Guin JD. Contact sensitivity to topical corticosteroids. J Am Acad Dermatol 1984; 10:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/27\">",
"      Tadicherla S, Ross K, Shenefelt PD, Fenske NA. Topical corticosteroids in dermatology. J Drugs Dermatol 2009; 8:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/28\">",
"      Coopman S, Degreef H, Dooms-Goossens A. Identification of cross-reaction patterns in allergic contact dermatitis from topical corticosteroids. Br J Dermatol 1989; 121:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/29\">",
"      Walsh P, Aeling JL, Huff L, Weston WL. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol 1993; 29:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/30\">",
"      Keipert JA, Kelly R. Temporary Cushing's syndrome from percutaneous absorption of betamethasone 17-valerate. Med J Aust 1971; 1:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/31\">",
"      Katz HI, Hien NT, Prawer SE, et al. Superpotent topical steroid treatment of psoriasis vulgaris--clinical efficacy and adrenal function. J Am Acad Dermatol 1987; 16:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/32\">",
"      BECKER B. CATARACTS AND TOPICAL CORTICOSTEROIDS. Am J Ophthalmol 1964; 58:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/33\">",
"      du Vivier A, Stoughton RB. Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol 1975; 111:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/34\">",
"      du Vivier A. Tachyphylaxis to topically applied steroids. Arch Dermatol 1976; 112:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/35\">",
"      Singh G, Singh PK. Tachyphylaxis to topical steroid measured by histamine-induced wheal suppression. Int J Dermatol 1986; 25:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/36\">",
"      Miller JJ, Roling D, Margolis D, Guzzo C. Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis. J Am Acad Dermatol 1999; 41:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/37\">",
"      Feldman SR. Tachyphylaxis to topical corticosteroids: the more you use them, the less they work? Clin Dermatol 2006; 24:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/38\">",
"      Long CC, Finlay AY. The finger-tip unit--a new practical measure. Clin Exp Dermatol 1991; 16:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/39\">",
"      Wilson R, Camacho F, Clark AR, et al. Adherence to topical hydrocortisone 17-butyrate 0.1% in different vehicles in adults with atopic dermatitis. J Am Acad Dermatol 2009; 60:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/40\">",
"      Smith ES, Fleischer AB Jr, Feldman SR. Nondermatologists are more likely than dermatologists to prescribe antifungal/corticosteroid products: an analysis of office visits for cutaneous fungal infections, 1990-1994. J Am Acad Dermatol 1998; 39:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/41\">",
"      Barkey WF. Striae and persistent tinea corporis related to prolonged use of betamethasone dipropionate 0.05% cream/clotrimazole 1% cream (Lotrisone cream). J Am Acad Dermatol 1987; 17:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27752/abstract/42\">",
"      Reynolds RD, Boiko S, Lucky AW. Exacerbation of tinea corporis during treatment with 1% clotrimazole/0.05% betamethasone diproprionate (Lotrisone). Am J Dis Child 1991; 145:1224.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5565 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-A93D27A9D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_6_27752=[""].join("\n");
var outline_f27_6_27752=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1591875\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VEHICLE SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ointments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Creams",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lotions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Solutions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Wet dressings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Foams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TOPICAL CORTICOSTEROIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Potency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Corticosteroid selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treatment duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Use in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Use during pregnancy or lactation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Cutaneous",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Systemic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1591664\">",
"      Tachyphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      INTRALESIONAL CORTICOSTEROID",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PITFALLS OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Suboptimal medication use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Patient compliance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Combination antifungal/topical corticosteroid products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1591875\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5565\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5565|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/52/11075\" title=\"figure 1\">",
"      Cross-reactivity of topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5565|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/11/5308\" title=\"table 1\">",
"      Vehicle selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 2\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/19/31035\" title=\"table 3\">",
"      Amount of topical medications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=related_link\">",
"      Intralesional injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=related_link\">",
"      Rosacea: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=related_link\">",
"      Treatment of psoriasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_6_27753="Transplant glomerulopathy EM";
var content_f27_6_27753=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F79914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F79914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transplant glomerulopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph of transplant glomerulopathy reveals marked narrowing of the vascular lumen due to widening of the subenthothelial space both by mesangial cell processes (arrow) and by amorphous, electron-lucent material.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Electron micrograph of a normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron dense deposits are present. Two normal platelets are seen in the capillary lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_6_27753=[""].join("\n");
var outline_f27_6_27753=null;
var title_f27_6_27754="Primary (spontaneous) upper extremity deep vein thrombosis";
var content_f27_6_27754=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary (spontaneous) upper extremity deep vein thrombosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/6/27754/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/6/27754/contributors\">",
"     Kaoru Goshima, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/6/27754/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/6/27754/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/6/27754/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/6/27754/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/6/27754/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/6/27754/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary, \"spontaneous\" upper extremity deep vein thrombosis is rare and is defined as thrombosis of the deep veins draining the upper extremity due to anatomic abnormalities of the thoracic outlet causing axillosubclavian compression and subsequent thrombosis. The syndrome is appropriately termed venous thoracic outlet syndrome, but is also referred to as Paget-Schroetter syndrome, and alternatively as &lsquo;effort&rsquo; thrombosis&rsquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/1\">",
"     1",
"    </a>",
"    ]. It typically presents in young, otherwise healthy individuals as sudden, severe upper extremity pain and swelling following vigorous upper extremity activity. An aggressive treatment approach that includes anticoagulation, catheter-directed thrombolysis and thoracic outlet decompression is aimed at relieving acute symptoms, and minimizing complications including recurrent thromboembolism and post-thrombotic syndrome.",
"   </p>",
"   <p>",
"    The epidemiology, risk factors, pathophysiology, clinical features, diagnosis and treatment of primary (spontaneous) upper extremity venous thrombosis will be reviewed here. Catheter-induced upper extremity venous thrombosis and lower extremity deep vein thrombosis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link\">",
"     \"Catheter-induced upper extremity venous thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=see_link\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H185996549\">",
"    <span class=\"h1\">",
"     UPPER EXTREMITY ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The upper extremity veins are divided into the superficial and deep venous systems (",
"    <a class=\"graphic graphic_figure graphicRef55596 \" href=\"UTD.htm?18/3/18480\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H185996601\">",
"    <span class=\"h2\">",
"     Superficial veins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main superficial veins of the upper extremity include the cephalic, basilic, median cubital, and accessory cephalic veins (",
"    <a class=\"graphic graphic_figure graphicRef55596 \" href=\"UTD.htm?18/3/18480\">",
"     figure 1",
"    </a>",
"    ). The basilic vein is a common access site for performing digital subtraction venography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H185996608\">",
"    <span class=\"h2\">",
"     Deep veins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The deep veins of the upper extremity include the paired ulnar, radial and interosseous veins in the forearm, paired brachial veins of the upper arm, and axillary vein. The axillary vein becomes the subclavian vein at the lower border of the teres major muscle (",
"    <a class=\"graphic graphic_figure graphicRef61941 \" href=\"UTD.htm?15/43/16053\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186006964\">",
"    <span class=\"h2\">",
"     Thoracic outlet anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thoracic outlet is bounded by the bony structures of the spinal column, first ribs, and sternum (",
"    <a class=\"graphic graphic_figure graphicRef59433 \" href=\"UTD.htm?17/58/18338\">",
"     figure 3A",
"    </a>",
"    ). Compression of the venous structures that traverse the thoracic outlet occurs in two distinct spaces: the scalene triangle and the costoclavicular space.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Scalene triangle &ndash; The anterior border of the scalene triangle is formed by the anterior scalene muscle, which originates from the transverse processes of the third through sixth cervical vertebrae (C3-C6) and inserts on the inner borders and superior surfaces of the first rib. The posterior wall of the scalene triangle is formed by the middle scalene muscle, which arises from the transverse processes of the second through seventh cervical vertebrae (C2-C7) and inserts broadly onto the posterior aspects of the first rib. The superior border of the first rib forms the base of the scalene triangle. The trunks of the brachial plexus and the subclavian artery pass between the anterior and middle scalene muscles, while the subclavian vein courses anteromedial to the scalene triangle (",
"      <a class=\"graphic graphic_figure graphicRef50430 \" href=\"UTD.htm?38/46/39650\">",
"       figure 3B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Costoclavicular space &ndash; The costoclavicular space comprises the area between the first rib and the clavicle. The brachial plexus, subclavian artery and subclavian vein pass through this space. The subclavian vein is most likely to be compressed at this site.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H239061107\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary upper extremity deep vein thrombosis is defined as thrombosis of the deep veins draining the upper extremity due to an underlying anatomic anomaly at the thoracic outlet causing compression or repetitive injury to the underlying axillosubclavian vein [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Primary upper extremity deep vein thrombosis is a manifestation of venous thoracic outlet syndrome (vTOS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3177?source=see_link&amp;anchor=H455545401#H455545401\">",
"     \"Overview of thoracic outlet syndromes\", section on 'Venous TOS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thrombosis of the veins draining the upper extremity was originally postulated to be the cause of acute arm pain and swelling by Paget [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/6\">",
"     6",
"    </a>",
"    ], and later Von Schroetter related the clinical syndrome specifically to the axillary and subclavian veins [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/7\">",
"     7",
"    </a>",
"    ]. This clinical entity was referred to as Paget-Schroetter syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/8\">",
"     8",
"    </a>",
"    ]. In the mid-20th century, the term &lsquo;effort&rsquo; thrombosis was coined [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/9\">",
"     9",
"    </a>",
"    ], due to the fact that the syndrome often occurred in physically active individuals after unusually strenuous use of the arm and shoulder [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. The term \"spontaneous\" upper extremity venous thrombosis has also been used highlighting the often dramatic presentation in an otherwise healthy, young individual. For the purposes of our discussion, we will refer to the syndrome as primary upper extremity deep vein thrombosis to distinguish it from secondary causes, which are associated with inciting factors such as indwelling catheters or prothrombotic states. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link\">",
"     \"Catheter-induced upper extremity venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anatomic abnormalities of the thoracic outlet that result in compression of the vein can be congenital or acquired. Congenital anomalies consist of cervical ribs, supernumerary muscles, abnormal tendon insertions or abnormal muscular or tendinous bands [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Acquired abnormalities include bony overgrowth due to bony fracture (eg, clavicle, first rib) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/15-18\">",
"     15-18",
"    </a>",
"    ], or hypertrophy of anterior scalene muscle or subclavius muscles, often related to repetitive lifting. The abnormalities of the thoracic outlet are often bilateral, and bilateral primary upper extremity deep vein thrombosis has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Anatomic abnormalities narrow the scalene triangle, or more commonly the costoclavicular space, predisposing the vein to compression between the first rib and muscle or tendon (",
"    <a class=\"graphic graphic_figure graphicRef59433 graphicRef50430 \" href=\"UTD.htm?37/29/38359\">",
"     figure 3A-B",
"    </a>",
"    ), or between anomalous tendon insertions. Less commonly, compression of the vein between the clavicle and a cervical rib can occur, and partial occlusion of the vein by a congenital web has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H186006964\">",
"     'Thoracic outlet anatomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Under some circumstances, it appears that an anatomic abnormality is not necessary to produce injury to the vein. Extremes in range of motion of the upper extremity can lead to movement of the clavicle relative to the first rib sufficient to cause venous compression. Repetitive overhead arm movements or hyperabduction and external rotation of the shoulder are most often implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Repetitive injury causes perivenous fibrosis, which eventually leads to thrombosis. It is important to recognize that the patient often presents with acute onset of symptoms related to the thrombosis, but the underlining problem may be a chronic repetitive injury that had narrowed the vein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H239061271\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper extremity deep vein thrombosis (all causes) represents 1 to 4 percent of all cases of deep vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/24\">",
"     24",
"    </a>",
"    ]. Primary upper extremity deep vein thrombosis is rare with an estimated annual incidence of 1 to 2 cases per 100,000 population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/10,24\">",
"     10,24",
"    </a>",
"    ]. The majority of cases of upper extremity deep vein thrombosis are due to secondary causes of venous thrombosis related to central venous cannulation (eg, central line, pacemaker) or prothrombotic states (eg, thrombophilia, malignancy) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/1,10,25,26\">",
"     1,10,25,26",
"    </a>",
"    ] (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link\">",
"     \"Catheter-induced upper extremity venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Between 60 and 80 percent of patients with primary upper extremity deep vein thrombosis report a history of exercise or strenuous activity involving usually the dominant upper extremity prior to the onset of symptoms. Strenuous activities include weight-lifting, rowing, or activities involving repetitive overhead arm movements, particularly hyperabduction, such as pitching [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/1,27,28\">",
"     1,27,28",
"    </a>",
"    ]. The average age at presentation is in the early thirties and the male to female ratio is 2:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/1\">",
"     1",
"    </a>",
"    ]. A predominance of right-handed individuals may explain why the right axillosubclavian vein is more commonly affected. (See",
"    <a class=\"local\" href=\"#H239061107\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H239061389\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for primary upper extremity deep vein thrombosis include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/1,10,25-28\">",
"     1,10,25-28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Younger age",
"     </li>",
"     <li>",
"      Athletic muscular male",
"     </li>",
"     <li>",
"      Strenuous upper extremity activity",
"     </li>",
"     <li>",
"      Repetitive overarm hyperabduction",
"     </li>",
"     <li>",
"      Anatomic abnormalities of the thoracic outlet (congenital, acquired)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary upper extremity deep vein thrombosis can present acutely with symptoms and signs of upper extremity deep vein thrombosis or pulmonary embolism, or with chronic or intermittent symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351070\">",
"    <span class=\"h2\">",
"     Acute upper extremity deep vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute presentations are due to sudden thrombosis of the axillosubclavian vein.",
"   </p>",
"   <p>",
"    The classic presentation is that of a young, athletic male presenting with an acute onset of upper extremity pain and swelling in their dominant arm following a particularly strenuous activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/1,27,28\">",
"     1,27,28",
"    </a>",
"    ]. Strenuous use of the arm prior to the onset of extremity swelling or pain is recalled in 40 to 80 percent of patients, and symptoms are generally noticed within 24 hours of the strenuous activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/10,11,23,29\">",
"     10,11,23,29",
"    </a>",
"    ]. The majority of patients (70 to 80 percent) manifest with variable degrees of neck, shoulder, or axillary discomfort, arm heaviness and pain associated with complaints of upper extremity swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Swelling and pain typically improve with rest and elevation of the arm to the level of the heart, whereas elevation of the extremity overhead may aggravate the symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physical examination generally reveals edema of the affected extremity, often accompanied by cyanosis of the hand and fingers. The patient may also have a low-grade fever. A palpable venous cord (superficial thrombophlebitis) may be apparent in associated superficial veins (eg, proximal cephalic vein). Dilated subcutaneous collateral veins, also known as Urschel&rsquo;s sign, may be noticeable over the upper chest and proximal upper extremity, particularly in those with an underlying chronic venous stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/11,27,30\">",
"     11,27,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The upper extremity arterial vascular examination should be normal. Reduced arterial blood flow due to venous congestion (phlegmasia cerulea dolens) is rare in the lower extremity and even more so in the upper extremity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. However, if present, it represents an emergency and indicates the need for emergent treatment. (See",
"    <a class=\"local\" href=\"#H185996469\">",
"     'Thrombolytic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Coexistent signs related to brachial plexus compression (ie, neurogenic thoracic outlet syndrome) may be present, manifesting as paraesthesias or pain in the ulnar nerve distribution, tenderness over the supraclavicular fossa, and wasting of the intrinsic hand muscles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3177?source=see_link&amp;anchor=H293627701#H293627701\">",
"     \"Overview of thoracic outlet syndromes\", section on 'Clinical evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351144\">",
"    <span class=\"h2\">",
"     Acute pulmonary embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to upper extremity swelling and pain, upper extremity deep vein thrombosis can initially present as symptomatic or asymptomatic pulmonary embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/12,28,31,35-39\">",
"     12,28,31,35-39",
"    </a>",
"    ]. The clinical features, diagnosis and treatment of pulmonary embolism are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=see_link\">",
"     \"Overview of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351151\">",
"    <span class=\"h2\">",
"     Chronic or intermittent symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with partial thrombosis or chronic venous stenosis due to repetitive injury that causes activity-related obstruction, symptoms may be intermittent and less severe. If venous occlusion develops over a protracted period of time, edema or pain may be minimal, and increased venous collateral flow over the chest (Urschel&rsquo;s sign) may be the only clinical sign that is apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/11,27,30,40\">",
"     11,27,30,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H185997417\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of upper extremity venous outflow obstruction (ie, deep vein thrombosis or venous stenosis) may be suspected based upon the clinical presentation, but should be confirmed with imaging, typically initially using ultrasound. D-dimer is useful for excluding thrombosis as an etiology, but will not exclude venous stenosis without thrombosis as a source of symptoms. Once a diagnosis of venous outflow obstruction is established, a primary etiology should be sought to identify the underlying anatomic abnormality that is the source of the obstruction. We obtain a plain chest radiograph on all patients to identify any obvious bony abnormalities; however, more advanced imaging may be needed to demonstrate abnormal muscular attachments. It is important to assess contralateral limb involvement because about half of patients will have some degree of contralateral venous obstruction, even in the absence of symptoms. (See",
"    <a class=\"local\" href=\"#H239061107\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1387789930\">",
"    <span class=\"h2\">",
"     D-dimer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma D-dimer, which is a degradation product of cross-linked fibrin, may be elevated in patients with upper extremity deep vein thrombosis, as in those with other lower extremity deep vein thrombosis or pulmonary embolism. However, although a plasma D-dimer &gt;500",
"    <span class=\"nowrap\">",
"     &micro;g/L",
"    </span>",
"    is sensitive for thrombosis, and has a high negative predictive value, it is not specific for the anatomic location of the thrombosis, but will not exclude vein",
"    <span class=\"nowrap\">",
"     compression/stenosis",
"    </span>",
"    as a source for symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H239062098\">",
"    <span class=\"h2\">",
"     Venous outflow obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;B-mode ultrasound, color Doppler ultrasound, and duplex ultrasound have been used extensively in the diagnosis of deep vein obstruction. Noncompressibility of the vein on B-mode ultrasound with or without visible intraluminal thrombus is the major criterion for the diagnosis of venous thrombosis. We use duplex ultrasound as the initial test for diagnosing upper extremity venous outflow obstruction because it is noninvasive, inexpensive, and in observational studies, has an acceptable sensitivity and specificity for the diagnosis of upper extremity deep vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/31,42-49\">",
"     31,42-49",
"    </a>",
"    ]. A systematic review evaluated 17 studies, concluding that compression ultrasonography is an acceptable alternative to standard contrast venography [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/42\">",
"     42",
"    </a>",
"    ]. The summary estimates of the sensitivity of compression, Doppler ultrasound, and Doppler ultrasound with compression were 97, 84, and 81 percent, respectively, and specificities were 96, 94, and 93 percent, respectively. Disadvantages of ultrasound are that it is technician-dependent, and that nonocclusive mural thrombus and thrombus in the proximal subclavian or innominate veins may not be adequately seen as a result of acoustic shadowing by the overlying clavicle and sternum [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/48,50,51\">",
"     48,50,51",
"    </a>",
"    ]. However, proximal subclavian vein obstruction is less typical of primary causes of upper extremity venous outflow obstruction, which tends to affect the mid- to distal",
"    <span class=\"nowrap\">",
"     subclavian/proximal",
"    </span>",
"    axillary vein at the thoracic outlet. When acoustic shadowing is a problem, venous thrombus or stenosis more proximal to the placement of the ultrasound probe can be inferred from abnormal respiratory variation, abnormal augmentation, and abnormal Doppler flow.",
"   </p>",
"   <p>",
"    Although standard catheter-based (digital subtraction) venography provides the best definition of abnormal venous anatomy and is the standard with which other modalities are compared [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/42,52\">",
"     42,52",
"    </a>",
"    ], it is generally not needed to establish a diagnosis of upper extremity deep vein thrombosis. Venography requires cannulation of a peripheral vein of the affected upper extremity, which can be challenging in the face of significant extremity edema, and the study requires a substantial intravenous contrast load. As such, catheter-based venography is generally reserved for situations where noninvasive studies are equivocal, but clinical suspicion remains high for a primary cause of venous outlet obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/1\">",
"     1",
"    </a>",
"    ]. For patients with intermittent or chronic symptoms, extrinsic compression of the vein can be demonstrated during catheter-based venography by performing dynamic studies that place the arm in various positions during the study. The venogram may be normal at rest but abnormal (varying degrees of extrinsic compression with &ldquo;new&rdquo; venous collaterals) with arm abduction; however, vein compression with arm abduction can be a normal variant [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/53\">",
"     53",
"    </a>",
"    ] Bony abnormalities may also be seen with fluoroscopic imaging during catheter-based venography, but abnormal fibrous bands or muscle insertions will not.",
"   </p>",
"   <p>",
"    Less invasive methods of venography include computed tomographic (CT) and magnetic resonance (MR) venography [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/51,54-56\">",
"     51,54-56",
"    </a>",
"    ]. These modalities are not typically used to establish a diagnosis of upper extremity venous outflow obstruction. Rather, these studies are more useful for identifying anatomic abnormalities and other secondary causes for deep vein thrombosis (eg, tumor). (See",
"    <a class=\"local\" href=\"#H239062150\">",
"     'Anatomic abnormalities of the thoracic outlet'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CT venography can be used to confirm or exclude central vein thrombus; however, like catheter-based venography, substantial contrast loads are required. CT venography has not been studied sufficiently to determine its sensitivity and specificity. A small study of 18 patients compared CT venography and digital subtraction venography for their ability to discriminate the severity and extent of venous obstruction, the cause of upper extremity deep vein thrombosis, and implications for the planning of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/56\">",
"       56",
"      </a>",
"      ]. CT venography was felt to provide more information than digital subtraction venography, and in half of the patients, the findings of CT venography changed the treatment plan.",
"     </li>",
"     <li>",
"      Magnetic resonance imaging is very specific in its ability to image subclavian vein thrombosis, but its sensitivity for thrombosis is too low to be a useful screening modality [",
"      <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/51\">",
"       51",
"      </a>",
"      ]. In one study comparing standard catheter-based venography to time of flight (TOF) magnetic resonance (MR) venography and gadolinium 3-D MR venography in 31 patients, sensitivities and specificities were 71 and 89 percent for TOF MRV, and 50 and 80 percent gadolinium 3D MRV, respectively. In this study, 10 of 21 patients were unable to undergo MR venography [",
"      <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H239062150\">",
"    <span class=\"h2\">",
"     Anatomic abnormalities of the thoracic outlet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a diagnosis of upper extremity venous outflow obstruction is established, further imaging should be performed to identify a primary cause for thrombosis, such as cervical ribs, supernumerary ribs, abnormal bands or abnormal muscle insertions. For any patient suspected of having a primary cause for upper extremity deep vein thrombosis or stenosis, we obtain a plain chest film to identify any bony abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/57\">",
"     57",
"    </a>",
"    ]. Ideally, the anatomic abnormality should be identified prior to thoracic outlet decompression; however, this is not always possible. At times, the anatomic abnormality may not be apparent until the time of surgical exploration. (See",
"    <a class=\"local\" href=\"#H185996871\">",
"     'Thoracic outlet decompression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although computed tomography (CT) and magnetic resonance (MR) imaging are less appropriate initial studies for screening patients suspected of having upper extremity deep vein thrombosis, these studies provide more anatomic detail and show the relationship of venous structures to the surrounding bone and muscle. CT and MRI also allow the assessment of central venous stenosis or occlusion, which can be missed by ultrasound due to acoustic shadowing from overlying bony structures. In addition, less obvious bony abnormalities can be seen on these studies, and at times, venous compression related to bony or muscular abnormalities can also be seen.",
"   </p>",
"   <p>",
"    In the absence of an obvious bony anatomic abnormality, a primary cause for the thrombosis or venous stenosis can be presumed in the young, otherwise healthy, active individual with a classic presentation who does not have a history of central venous instrumentation or other medical problems associated with secondary etiologies for venous outflow obstruction. The specific abnormality may not be determined until the time of surgical exploration. (See",
"    <a class=\"local\" href=\"#H239066343\">",
"     'Approach to treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25075587\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for upper extremity edema not related to primary upper extremity deep vein thrombosis includes edema related to other etiologies, secondary causes of venous thrombosis, and lymphedema.",
"   </p>",
"   <p>",
"    Primary upper extremity deep vein thrombosis can be distinguished from secondary causes by the absence of venous instrumentation, a young, otherwise healthy patient demographic, and a more typically sudden onset of symptoms. The clinical features of upper extremity deep vein thrombosis are otherwise similar and include upper extremity edema and pain, and cyanosis of the skin due to venous congestion. Upper extremity deep vein thrombosis that occurs in the absence of instrumentation and with no identifiable anatomic abnormalities or other risk factors for venous thrombosis (eg, oral contraceptives) raises a concern of occult malignancy. Up to 25 percent of patients will be diagnosed within one year of a venous thromboembolic event [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/31,58\">",
"     31,58",
"    </a>",
"    ]. If a primary cause for upper extremity deep vein thrombosis is not immediately apparent on imaging studies, the patient has no history of instrumentation, and the patient has none of the risk factors listed above for primary upper extremity deep venous thrombosis, we suggest a more formal laboratory evaluation to rule out secondary causes for upper extremity deep vein thrombosis, including coagulation studies, which should be drawn prior to the initiation of anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=see_link\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link\">",
"     \"Hypercoagulable disorders associated with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with venous thrombosis due to compression of structures of the thoracic outlet may also have symptoms attributable to the arterial or neurologic structures that pass through this space. Distinguishing between neurogenic, arterial, and venous thoracic outlet syndrome is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3177?source=see_link&amp;anchor=H293627701#H293627701\">",
"     \"Overview of thoracic outlet syndromes\", section on 'Clinical evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are many causes of extremity edema that are not related to venous obstruction. The medical history will usually give a clue as to the potential etiology for edema (eg, history of heart failure). Although systemic etiologies typically present with bilateral extremity edema, this feature is not helpful given that anatomic abnormalities of the thoracic outlet are common and patients with primary upper extremity deep vein thrombosis can present with bilateral symptoms. Routine laboratory studies typically important in the evaluation of patients with extremity edema include a complete blood count, electrolytes, and liver function tests. These studies may point to an alternative etiology for upper extremity edema. The general approach to the patient with edema is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/34/36393?source=see_link\">",
"     \"Pathophysiology and etiology of edema in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34375?source=see_link\">",
"     \"Clinical manifestations and diagnosis of edema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Upper extremity arm swelling can be due to lymphedema; however, swelling from acute venous thrombosis has a more abrupt onset and an antecedent risk factor such as prior axillary lymph node dissection is lacking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link\">",
"     \"Clinical manifestations and diagnosis of lymphedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H239066343\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of treatment of primary upper extremity deep vein thrombosis are relieving symptoms related to venous obstruction, preventing complications of deep vein thrombosis, and preventing recurrent thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/59\">",
"     59",
"    </a>",
"    ]. Treatment options include anticoagulation, thrombolysis, and surgical decompression of the thoracic outlet. No treatment or combination of treatments has been rigorously evaluated for the treatment of upper extremity deep vein thrombosis. As a result, recommendations are based upon available retrospective studies and indirect evidence provided from the experience with deep vein thrombosis of the lower extremity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our approach to treatment is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We agree with guidelines from the American College of Chest Physicians that recommend anticoagulation for a minimum of three months for all patients identified with upper extremity deep vein thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/60\">",
"       60",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H239064388\">",
"       'Anticoagulation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For patients with primary upper extremity axillosubclavian deep vein thrombosis with sudden onset, moderate-to-severe upper extremity symptoms of less than two weeks duration, we suggest thrombolysis to eliminate thrombus to the extent that is possible. Lysis is less effective when symptoms have been present for more than two weeks. (See",
"      <a class=\"local\" href=\"#H185996469\">",
"       'Thrombolytic therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For good-risk surgical patients identified with anatomic abnormalities of the thoracic outlet causing symptomatic venous compression, we suggest thoracic outlet decompression. The specific procedure is targeted to the type of abnormality identified. For those in whom a specific abnormality has not been identified, we perform first rib resection, provided that a secondary cause of upper extremity venous thrombosis is not present.",
"     </li>",
"     <li>",
"      Anticoagulation alone (no thrombolysis) with or without thoracic outlet decompression may be appropriate for patients with mild symptoms, intermittent symptoms, and those who present in a delayed manner (&gt;2 weeks). The natural history of these patients is unclear. (See",
"      <a class=\"local\" href=\"#H239065433\">",
"       'Symptomatic care'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H239064388\">",
"       'Anticoagulation'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352775\">",
"    <span class=\"h2\">",
"     Rationale for aggressive treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;An aggressive approach that includes a combination of thrombolysis and thoracic outlet decompression with or without venoplasty (percutaneous, open) appears to improve long-term outcomes in patients with primary upper extremity deep vein thrombosis, particularly those with acute, moderate-to-severe symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/61-82\">",
"     61-82",
"    </a>",
"    ]. With an aggressive approach, success rates for re-establishing subclavian vein patency are nearly 100 percent provided that thrombolysis is performed within two weeks of the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. Although early intervention is advocated, patients with primary upper extremity deep vein thrombosis who present later than two weeks may also benefit from thoracic outlet decompression (no thrombolysis) given the high rates of recurrent thrombosis and long-term morbidity associated with anticoagulation alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/3,22,86,87\">",
"     3,22,86,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a worldwide clinical series of 606 patients with primary upper extremity deep vein thrombosis, early thrombolysis and first rib resection provided the best outcome, with 95 percent of the surgical cohort experiencing an excellent clinical outcome compared with 29 percent treated conservatively, which consisted of anticoagulation, arm elevation, and upper extremity compression [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/27\">",
"     27",
"    </a>",
"    ]. Residual venous obstruction was present in 78 percent of patients. The clinical outcomes associated with anticoagulation alone were evaluated in a later series of 54 patients, nearly all of whom were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/21\">",
"     21",
"    </a>",
"    ]. After a mean follow-up of five years, 22 percent had persistent severe venous outflow obstruction on follow-up ultrasound. About 50 percent of the patients were asymptomatic, but 13 percent had severe or disabling symptoms. Subsequent pulmonary embolism was documented in 26 percent and was symptomatic in one-third of the patients. By comparison, among patients treated with thrombolysis (without thoracic outlet decompression), 76 percent were asymptomatic after a mean follow-up of 55 months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/21,83\">",
"     21,83",
"    </a>",
"    ]. In other retrospective reviews, persistent symptoms and disability occurred in 41 to 91 percent of patients treated conservatively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/1,27\">",
"     1,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    First rib resection without preoperative thrombolysis has been proposed for the management of primary subacute venous thrombosis. In the retrospective review, 45 of 110 patients underwent preoperative thrombolysis alone or thrombolysis and balloon venoplasty prior to thoracic outlet decompression. The remaining 65 patients were treated with anticoagulation alone prior to thoracic outlet decompression. Up to 80 percent of occluded axillosubclavian veins recanalized during the follow-up period in the anticoagulation group, and the overall rates of venous patency were similar between the groups [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1387792888\">",
"    <span class=\"h2\">",
"     Recommendations of others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our recommendations are in general agreement with the guidelines from the American College of Chest Physicians (ACCP); however, the ACCP suggests anticoagulant therapy alone over thrombolysis for patients with acute upper extremity deep vein thrombosis that involves the axillary or more proximal veins [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/60\">",
"     60",
"    </a>",
"    ]. They further state that patients are likely to choose thrombolytic therapy over anticoagulation alone if they are more likely to benefit from thrombolysis, have access to catheter-based therapy, attach a high value to the prevention of post-thrombotic syndrome, and attach a lower value to the initial complexity, cost, and risk of bleeding with thrombolytic therapy. This recommendation does not distinguish between primary and secondary causes of upper extremity deep vein thrombosis directly; however, given that patients with primary upper extremity deep vein thrombosis are more likely to benefit from thrombolysis compared with patients with secondary causes of deep vein thrombosis, we support a more aggressive treatment strategy. (See",
"    <a class=\"local\" href=\"#H352775\">",
"     'Rationale for aggressive treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H239064139\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are diagnosed with primary upper extremity deep vein thrombosis are initially managed with measures to improve their comfort and are anticoagulated. Anticoagulation helps to maintain patency of collateral veins and reduces propagation of thrombus. Anticoagulant therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is also effective in preventing pulmonary embolism with lower extremity venous thrombosis, and by extrapolation, may also prevent embolism from upper extremity deep vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/28,60\">",
"     28,60",
"    </a>",
"    ]. The decision to proceed with thrombolysis or thoracic outlet decompression is based upon symptom severity and the type of associated anatomic abnormality. (See",
"    <a class=\"local\" href=\"#H239066343\">",
"     'Approach to treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H239065433\">",
"    <span class=\"h2\">",
"     Symptomatic care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic care of phlebitic symptoms related to upper extremity deep vein thrombosis includes upper extremity elevation, and nonsteroidal anti-inflammatory drugs (NSAIDs) for pain management.",
"   </p>",
"   <p>",
"    Arm elevation should help reduce upper extremity swelling. Graduated compression stockings have been shown to reduce the rate of post-thrombotic syndrome in patients with lower extremity deep vein thrombosis, and may also be beneficial in patients with upper extremity deep vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/31\">",
"     31",
"    </a>",
"    ]. However, compression is likely unnecessary in treated patients for whom the lesion is corrected and edema has resolved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H239064388\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with guidelines from the American College of Chest Physicians that recommend parenteral anticoagulation (eg, low molecular-weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    , intravenous unfractionated heparin, subcutaneous unfractionated heparin) for all patients with axillosubclavian vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/60\">",
"     60",
"    </a>",
"    ]. In our practice, we begin parenteral anticoagulation once a diagnosis of deep vein thrombosis is made but after any necessary laboratory tests to evaluate for hypercoagulable states have been obtained. &nbsp;",
"   </p>",
"   <p>",
"    The choice of initial parenteral agent for anticoagulation in patients with primary upper extremity deep vein thrombosis depends upon the need for further treatment in the form of thrombolysis or thoracic outlet decompression. For patients with mild, intermittent, or chronic symptoms who will be managed on an outpatient basis, low molecular-weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMWH) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    can be initiated to bridge to long-term therapy in a similar fashion as those with lower extremity deep vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/60,88-90\">",
"     60,88-90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When thrombolysis is anticipated, we administer unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and maintain therapeutic levels (aPTT 1.5 to 2.5 times control) until thrombolysis is initiated. During thrombolysis, the dose of heparin should be lowered to minimize bleeding complications, but once thrombolysis is completed, full anticoagulation can be resumed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. Similarly, the dose of heparin should be lowered around the time of surgical intervention. Once any necessary interventions are completed, bridging anticoagulation can be use to transition to long-term therapy in anticipation of discharge. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link&amp;anchor=H2441429#H2441429\">",
"     \"Management of anticoagulation before and after elective surgery\", section on 'Bridging anticoagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H239067075\">",
"    <span class=\"h2\">",
"     Admission and referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with acute, severe symptoms related to primary upper extremity deep vein thrombosis will require admission to manage symptoms and in anticipation of thrombolytic therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical decompression.",
"   </p>",
"   <p>",
"    There is no \"one size fits all\" approach to the treatment of primary upper extremity deep vein thrombosis. Individualized care requires a team of specialists with sufficient experience and readily available resources and ancillary personnel. Such teams are rare outside tertiary referral centers, and thus, referral to a vascular center with such a team is appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/66,93\">",
"     66,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial outpatient anticoagulation and outpatient referral for possible further treatment may be appropriate for patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Minimal symptoms",
"     </li>",
"     <li>",
"      Delayed presentation more than two weeks after the onset of symptoms",
"     </li>",
"     <li>",
"      Intermittent symptoms due to venous obstruction without thrombosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H185996469\">",
"    <span class=\"h1\">",
"     THROMBOLYTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aim of thrombolytic therapy is prompt dissolution of thrombus to minimize inflammation and endothelial injury and to restore vein patency, which reduces extremity edema and associated symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/28,82,94,95\">",
"     28,82,94,95",
"    </a>",
"    ]. Thrombolytic therapy appears to have the most benefit for patients who present with acute, moderate-to-severe symptoms related to sudden axillosubclavian thrombosis. In our experience, thrombi that have been symptomatic for up to two weeks have a reasonable chance of lysis with catheter-directed infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    directed into the thrombus. Thrombolysis restores vein patency in 64 to 84 percent of patients, with better patency rates associated with earlier initiation of lytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/82\">",
"     82",
"    </a>",
"    ]. However, even after successful lysis that restores vein patency, up to one-third of patients will re-occlude [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/1,82\">",
"     1,82",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H352775\">",
"     'Rationale for aggressive treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The general contraindications to thrombolytic therapy are given in the table (",
"    <a class=\"graphic graphic_table graphicRef71568 \" href=\"UTD.htm?4/28/4555\">",
"     table 1",
"    </a>",
"    ). We do not perform thrombolysis in patients with only partial thrombosis, or those with mild acute or chronic, intermittent symptoms. Symptomatic patients who present more than two weeks after the onset of symptoms are less likely to benefit from thrombolysis due to the organized nature of the clot and inflammatory changes in the vein.",
"   </p>",
"   <p>",
"    Observational studies have shown that catheter-directed pharmacologic thrombolysis, which involves embedding an infusion catheter into the axillosubclavian vein thrombus, achieves higher rates of clot dissolution compared with systemic infusion and requires an overall lower dose and shorter duration of lysis, which reduces bleeding complications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/28,82,95\">",
"     28,82,95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Catheter-directed pharmacologic upper extremity thrombolysis is performed in the following manner:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The basilic vein of the affected limb is accessed using ultrasound guidance.",
"     </li>",
"     <li>",
"      A guidewire and catheter are used to traverse the thrombosed axillosubclavian vein.",
"     </li>",
"     <li>",
"      A multi sidehole infusion catheter is embedded within the thrombus and infusion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      initiated at 0.01",
"      <span class=\"nowrap\">",
"       mg/kg/hour",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/82,96\">",
"       82,96",
"      </a>",
"      ]. Alternatively, urokinase (not available in the United States) can be used [",
"      <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The catheter is sutured into position, and the patient transferred to a monitored setting to monitor for any bleeding complications. The progress of thrombolysis is evaluated by performing venography at 12 hours, and again at 24 hours if necessary. A total dose of 20 to 25 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      can be safely used in most cases.",
"     </li>",
"     <li>",
"      For patients undergoing catheter-directed or systemic thrombolysis,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      should be administered along with unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      during infusion of the thrombolytic agent to counteract platelet activation and potentially increased thrombogenicity that may be induced with lytic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mechanical thrombolysis (eg, Trellis, AngioJet, EKOS catheter) is often used in combination with pharmacologic thrombolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/98\">",
"     98",
"    </a>",
"    ]. There are limited data involving the use of these devices to treat upper extremity thrombosis. However, based upon available results for lower extremity deep vein thrombosis, these treatments may be useful in upper extremity thrombosis to rapidly extract a large burden of thrombus and reduce the overall dose and duration of lytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/99\">",
"     99",
"    </a>",
"    ]. Mechanical thrombolysis may be more effective for patients with acute, severe symptoms who present in a delayed manner (&gt;2 weeks) after the initial onset of symptoms.",
"   </p>",
"   <p>",
"    Once venous patency has been re-established with catheter-directed thrombolysis, it is important to evaluate the residual axillosubclavian vein for persistent stenosis. Occasionally, adjunctive percutaneous transluminal angioplasty (PTA) following successful thrombolysis is needed to open the vein sufficiently so that anticoagulant treatment can maintain patency until thoracic outlet decompression can be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H239067437\">",
"     'Venoplasty'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H185996871\">",
"     'Thoracic outlet decompression'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H185996871\">",
"    <span class=\"h1\">",
"     THORACIC OUTLET DECOMPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with primary upper extremity axillosubclavian deep vein thrombosis, and selected patients with axillosubclavian venous",
"    <span class=\"nowrap\">",
"     compression/stenosis,",
"    </span>",
"    observational studies support surgical decompression of the thoracic outlet, which provides the lower rates of recurrent (or future) thrombosis, and reduced long-term morbidity compared with more conservative management [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/1,27\">",
"     1,27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H352775\">",
"     'Rationale for aggressive treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Thoracic outlet decompression, which may include any one of a combination of the procedures discussed below, is indicated for good-risk surgical patients with any of the following presentations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/1,27,61,100,101\">",
"     1,27,61,100,101",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who present with acute, moderate to severe symptoms due to primary upper extremity axillosubclavian thrombosis, following thrombolysis.",
"     </li>",
"     <li>",
"      Symptomatic patients (intermittent or recurrent) with a thoracic outlet anatomic abnormality causing venous",
"      <span class=\"nowrap\">",
"       compression/stenosis.",
"      </span>",
"      Objective evidence of venous thrombosis may or may not be present.",
"     </li>",
"     <li>",
"      Thoracic outlet decompression may be indicated for an asymptomatic limb with venous",
"      <span class=\"nowrap\">",
"       compression/stenosis",
"      </span>",
"      contralateral to a symptomatic limb (current or prior symptoms), if the asymptomatic extremity is the dominant limb, or thrombosis is likely due to their occupation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Following successful thrombolysis, some clinicians favor anticoagulation for one to three months to allow endothelial healing and resolution of acute inflammation before thoracic outlet decompression [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/61\">",
"     61",
"    </a>",
"    ]. However, given the risk of re-thrombosis, we agree with the majority of surgeons in advocating surgical decompression during the same hospitalization as thrombolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/1,3,93\">",
"     1,3,93",
"    </a>",
"    ]. Regardless of the timing of surgical decompression, anticoagulation is maintained until the surgery can be performed. (See",
"    <a class=\"local\" href=\"#H239064388\">",
"     'Anticoagulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients with residual thrombus following thrombolysis or those with chronic axillosubclavian thrombosis, the axillosubclavian vein can be reconstructed concurrent with thoracic outlet decompression or at a later time using open or endovascular techniques, if needed. In a series of patients undergoing first rib resection for chronic symptoms related to primary subclavian vein thrombosis, subclavian vein thrombus resolved in 14 of 16 patients treated with ongoing anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/102\">",
"     102",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H239067437\">",
"     'Venoplasty'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The aim of thoracic outlet decompression is to provide more space through which the neurovascular structures of the upper extremity can pass. Thoracic outlet decompression may include any one or a combination of the following procedures, the choice of which will depend upon the specific anatomic abnormality identified [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/22,102\">",
"     22,102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3177?source=see_link&amp;anchor=H455545331#H455545331\">",
"     \"Overview of thoracic outlet syndromes\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      First rib resection",
"     </li>",
"     <li>",
"      Cervical rib resection (less common)",
"     </li>",
"     <li>",
"      Division of anomalous bands",
"     </li>",
"     <li>",
"      Division of anomalous musculotendinous insertions",
"     </li>",
"     <li>",
"      Scalenectomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients identified with a cervical rib, cervical rib resection may be all that is required. However, when a cervical rib is not present, first rib resection is combined with dissection and division of structures identified at the time of surgical exploration as potentially causing compression on the neurovascular structures of the thoracic outlet, whether or not these were identified as a specific source of compression on prior imaging studies.",
"   </p>",
"   <p>",
"    Three surgical approaches are used for thoracic outlet decompression: the transaxillary, supraclavicular, and infraclavicular approaches, each with advantages and disadvantages. There are no trials comparing surgical approaches for decompression, and there remains no expert consensus as to which surgical approach or method of treating the injured venous segment is better. As such, the surgical approach depends largely upon the type of anatomic abnormalities identified and surgeon preference. These approaches and the complications associated with them are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3177?source=see_link&amp;anchor=H293625095#H293625095\">",
"     \"Overview of thoracic outlet syndromes\", section on 'Thoracic outlet decompression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complications of thoracic outlet decompression include hemopneumothorax, long thoracic nerve injury, incomplete rib resection that can lead to recurrent symptoms, brachial plexus injury, arterial injury, lymphatic leak, and surgical site infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H239067437\">",
"    <span class=\"h1\">",
"     VENOPLASTY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is uniform agreement that thoracic outlet decompression should be performed early in patients with acute axillosubclavian thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/1\">",
"     1",
"    </a>",
"    ], debate exits over the management of the vein. Concurrent with thoracic outlet decompression, some feel that venolysis or venoplasty (percutaneous transluminal or open) is sufficient while others advocate vein repair (patch venoplasty, interposition vein graft, vein bypass, jugular turndown) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/27,77,103\">",
"     27,77,103",
"    </a>",
"    ]. There are insufficient data to support one approach over another.",
"   </p>",
"   <p>",
"    Occasionally, percutaneous transluminal angioplasty (PTA) is needed to keep the vein open following thrombolysis until thoracic outlet decompression can be accomplished [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/1\">",
"     1",
"    </a>",
"    ]. However, prior to thoracic outlet decompression, stenting should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/40,83,104-106\">",
"     40,83,104-106",
"    </a>",
"    ]. Shoulder movements subject the stent to repetitive compression that can lead to stent fracture. In one small observational study, stent use was found to be an independent risk factor for upper extremity rethrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/83\">",
"     83",
"    </a>",
"    ]. Once thoracic outlet decompression has been performed, whether or not a vein patch repair or bypass was performed, residual or recurrent stenosis may warrant PTA and possibly stenting, with acceptable clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/1,22\">",
"     1,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H185997649\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;We obtain a Duplex ultrasound in the postsurgical period to confirm patency of axillosubclavian vein. If the patient experiences recurrent symptoms, we agree with others in advocating an immediate venogram to evaluate the patency of the repaired venous segment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354750291\">",
"    <span class=\"h2\">",
"     Duration of anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with primary upper extremity deep vein thrombosis, anticoagulation should be continued for a minimum of three to six months following the initial thrombotic event, with a longer duration of therapy indicated for those who have had a recurrent event [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/60,107\">",
"     60,107",
"    </a>",
"    ]. We maintain anticoagulation regardless of whether intervention (thrombolysis, thoracic outlet decompression) was performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H239068450\">",
"    <span class=\"h1\">",
"     PERIOPERATIVE MORBIDITY AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality related to primary upper extremity deep vein thrombosis is overall low, due to the relatively young population of patients who are typically affected. By comparison, mortality related to secondary causes of upper extremity deep vein thrombosis is higher, ranging from 15 to 50 percent reflecting underlying co-morbidities such as malignancy, renal failure, and multi-organ failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112510524\">",
"    <span class=\"h2\">",
"     Recurrent thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent upper extremity deep vein thrombosis (all causes) occurs in 2 to 8 percent of patients following treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/28,108,109\">",
"     28,108,109",
"    </a>",
"    ]. These rates are significantly lower than recurrence rates for lower extremity deep vein thrombosis, which in one long term study was 30 percent at eight years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A hypercoagulable state needs to be considered in patients who develop recurrent thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/12\">",
"     12",
"    </a>",
"    ]. Higher rates of thrombophilia have been reported in patients with recurrent upper extremity deep vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/111-115\">",
"     111-115",
"    </a>",
"    ]. In one study, 90 percent of postoperative complications were associated with some form of thrombophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/112\">",
"     112",
"    </a>",
"    ]. The evaluation of thrombophilia is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link\">",
"     \"Evaluation of the patient with established venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H185996348\">",
"    <span class=\"h2\">",
"     Post-thrombotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-thrombotic syndrome refers to the development of symptoms or signs of chronic venous insufficiency related to a prior deep vein thrombosis. Post-thrombotic syndrome is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23127?source=see_link\">",
"     \"Post-thrombotic (postphlebitic) syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Quality of life is reduced in patients with post-thrombotic syndrome, particularly if the dominant arm is affected. Severe upper extremity symptoms with skin ulceration are rare, but post-thrombotic syndrome affecting the upper extremity can result in occupational disability in patients whose job requires manual labor. Even in patients whose occupation does not involve the vigorous use of the arms, symptoms of post-thrombotic syndrome can limit other activities and adversely impact quality of life.",
"   </p>",
"   <p>",
"    The incidence of post-thrombotic syndrome following upper extremity deep vein thrombosis (all causes) ranges from 7 to 44 percent but appears to be more prevalent following primary compared with secondary etiologies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/12,28\">",
"     12,28",
"    </a>",
"    ]. Since primary upper extremity deep vein thrombosis generally affects young, otherwise healthy individuals with an active lifestyle and long life-expectancy, one of the aims of early aggressive treatment is minimizing symptoms of post-thrombotic syndrome. (See",
"    <a class=\"local\" href=\"#H352775\">",
"     'Rationale for aggressive treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients with primary upper extremity deep vein thrombosis, up to 53 percent of patients treated with anticoagulation alone historically developed post-thrombotic syndrome at 5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/27,100\">",
"     27,100",
"    </a>",
"    ]. With aggressive therapy that includes anticoagulation, thrombolysis, and thoracic outlet decompression, the incidence of residual symptoms ranges from 12 to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/1,27\">",
"     1,27",
"    </a>",
"    ]. The risk of developing post-thrombotic syndrome may be greater in patients who have residual vein obstruction. However, in one study, no association between ultrasound findings and the development of post-thrombotic syndrome was found [",
"    <a class=\"abstract\" href=\"UTD.htm?27/6/27754/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93841183\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary, \"spontaneous\" upper extremity deep vein thrombosis is estimated to represent between 1 and 4 percent of all cases of upper extremity deep vein thrombosis, with secondary causes of thrombosis related to central vein cannulation (eg, central line, pacemaker) or prothrombotic states (eg, thrombophilia, malignancy) much more common. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary upper extremity deep vein thrombosis is defined as thrombosis of the deep veins draining the upper extremity (axillary, subclavian) due to an underlying anatomic anomaly at the thoracic outlet causing compression or repetitive venous injury. The syndrome is appropriately termed venous thoracic outlet syndrome, but is also referred to as Paget-Schroetter syndrome and &ldquo;effort&rdquo; thrombosis. Anatomic abnormalities can be congenital or acquired. Congenital anomalies consist of cervical ribs, supernumerary muscles, abnormal tendon insertions, or abnormal muscular or tendinous bands. Acquired abnormalities include bony overgrowth due to bony fracture (usually of the clavicle), or hypertrophy of anterior scalene muscle or subclavius muscles, often related to repetitive lifting. (See",
"      <a class=\"local\" href=\"#H239061107\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary upper extremity deep vein thrombosis typically presents in young, otherwise healthy individuals as sudden, severe arm swelling. Although more commonly associated with lower extremity deep vein thrombosis, pulmonary embolism from upper extremity deep vein thrombosis (primary and secondary) occurs in 4 to 10 percent of patients. The clinician should have a high index of suspicion for this disorder when a young patient with no inciting factors presents with signs of upper extremity venous thrombosis, or pulmonary embolism in the absence of lower extremity symptoms. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A diagnosis of upper extremity venous outflow obstruction (ie, deep vein thrombosis or venous stenosis) may be suspected based upon the clinical presentation, but should be confirmed with imaging, typically initially using ultrasound. D-dimer is useful for excluding thrombosis as an etiology, but will not exclude vein",
"      <span class=\"nowrap\">",
"       compression/stenosis",
"      </span>",
"      without thrombosis as a source of symptoms. Once a diagnosis of venous outflow obstruction is established, a primary etiology should be sought to identify the underlying anatomic abnormality that is the source of the obstruction. We obtain a plain chest radiograph on all patients to identify any obvious bony abnormalities. More advanced imaging may be necessary to demonstrate abnormal muscular attachments or dynamic venous compression. (See",
"      <a class=\"local\" href=\"#H185997417\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of primary upper extremity deep vein thrombosis is aimed at preventing pulmonary embolism, recurrent venous thrombosis and post-thrombotic syndrome. For patients with acutely symptomatic primary upper extremity deep vein thrombosis, we recommend anticoagulation over no such therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Anticoagulation helps to maintain patency of collateral veins, reduces propagation of thrombus, and is effective for preventing pulmonary embolism.",
"      <strong>",
"      </strong>",
"      We prefer to use unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      to facilitate rapid dose adjustment in patients who will undergo other interventions such as thrombolysis and thoracic outlet decompression.",
"     </li>",
"     <li>",
"      For patients with moderate to severe acute symptoms who are diagnosed with primary upper extremity deep vein thrombosis, we suggest thrombolysis over anticoagulation alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Following thrombolysis, we suggest thoracic outlet decompression, rather than no decompression (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This approach decreases the risk for recurrent thrombosis and post-thrombotic syndrome. Anticoagulation alone may be adequate for minimally symptomatic or intermittently symptomatic patients, and for those who present in a delayed manner (&gt;2 weeks from the onset of symptoms). (See",
"      <a class=\"local\" href=\"#H239066343\">",
"       'Approach to treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H352775\">",
"       'Rationale for aggressive treatment'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      We agree with American College of Chest Physicians who recommend a minimum of three months of anticoagulation following an initial thrombotic event. We maintain anticoagulation for a minimum of three months regardless of whether intervention (thrombolysis, thoracic outlet decompression) was performed. (See",
"      <a class=\"local\" href=\"#H239066343\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/1\">",
"      Illig KA, Doyle AJ. A comprehensive review of Paget-Schroetter syndrome. J Vasc Surg 2010; 51:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/2\">",
"      Alla VM, Natarajan N, Kaushik M, et al. Paget-schroetter syndrome: review of pathogenesis and treatment of effort thrombosis. West J Emerg Med 2010; 11:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/3\">",
"      Aziz S, Straehley CJ, Whelan TJ Jr. Effort-related axillosubclavian vein thrombosis. A new theory of pathogenesis and a plea for direct surgical intervention. Am J Surg 1986; 152:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/4\">",
"      Bahm J. Critical review of pathophysiologic mechanisms in thoracic outlet syndrome (TOS). Acta Neurochir Suppl 2007; 100:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/5\">",
"      Mustafa S, Stein PD, Patel KC, et al. Upper extremity deep venous thrombosis. Chest 2003; 123:1953.",
"     </a>",
"    </li>",
"    <li>",
"     Paget, J. Clinical lectures and essays. Longmen Green and Co, 1875.",
"    </li>",
"    <li>",
"     von Schroetter, L. Erkrankungen der Gefasse. In: Nathnagel Handbuch der Pathologie und Therapie, Anonymous Wein, Holder, 1884.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/8\">",
"      HUGHES ES. Venous obstruction in the upper extremity; Paget-Schroetter's syndrome; a review of 320 cases. Surg Gynecol Obstet 1949; 88:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/9\">",
"      Drapanas T, Curran WL. Thrombectomy in the treatment of \"effort\" thrombosis of the axillary and subclavian veins. J Trauma 1966; 6:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/10\">",
"      Lindblad B, Tengborn L, Bergqvist D. Deep vein thrombosis of the axillary-subclavian veins: epidemiologic data, effects of different types of treatment and late sequelae. Eur J Vasc Surg 1988; 2:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/11\">",
"      Horattas MC, Wright DJ, Fenton AH, et al. Changing concepts of deep venous thrombosis of the upper extremity--report of a series and review of the literature. Surgery 1988; 104:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/12\">",
"      Flinterman LE, Van Der Meer FJ, Rosendaal FR, Doggen CJ. Current perspective of venous thrombosis in the upper extremity. J Thromb Haemost 2008; 6:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/13\">",
"      Swinton NW Jr, Edgett JW Jr, Hall RJ. Primary subclavian-axillary vein thrombosis. Circulation 1968; 38:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/14\">",
"      Fisher JB, Granson MA. Congenital venous web causing subclavian vein obstruction: a case report. J Vasc Surg 1989; 10:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/15\">",
"      Johansen KH, Thomas GI. Late thoracic outlet syndrome secondary to malunion of the fractured clavicle: case report and review of the literature. J Trauma 2002; 52:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/16\">",
"      Jain S, Monbaliu D, Thompson JF. Thoracic outlet syndrome caused by chronic retrosternal dislocation of the clavicle. Successful treatment by transaxillary resection of the first rib. J Bone Joint Surg Br 2002; 84:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/17\">",
"      Duane TM, O'Connor JV, Scalea TM. Thoracic outlet syndrome resulting from first rib fracture. J Trauma 2007; 62:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/18\">",
"      Peivandi MT, Nazemian Z. Clavicular fracture and upper-extremity deep venous thrombosis. Orthopedics 2011; 34:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/19\">",
"      Stevenson IM, Parry EW. Radiological study of the aetiological factors in venous obstruction of the upper limb. J Cardiovasc Surg (Torino) 1975; 16:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/20\">",
"      Machleder HI. Thrombolytic therapy and surgery for primary axillosubclavian vein thrombosis: current approach. Semin Vasc Surg 1996; 9:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/21\">",
"      H&eacute;ron E, Lozinguez O, Emmerich J, et al. Long-term sequelae of spontaneous axillary-subclavian venous thrombosis. Ann Intern Med 1999; 131:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/22\">",
"      Urschel HC Jr, Razzuk MA. Paget-Schroetter syndrome: what is the best management? Ann Thorac Surg 2000; 69:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/23\">",
"      DiFelice GS, Paletta GA Jr, Phillips BB, Wright RW. Effort thrombosis in the elite throwing athlete. Am J Sports Med 2002; 30:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/24\">",
"      Isma N, Svensson PJ, Gotts&auml;ter A, Lindblad B. Upper extremity deep venous thrombosis in the population-based Malm&ouml; thrombophilia study (MATS). Epidemiology, risk factors, recurrence risk, and mortality. Thromb Res 2010; 125:e335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/25\">",
"      Engelberger RP, Kucher N. Management of deep vein thrombosis of the upper extremity. Circulation 2012; 126:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/26\">",
"      Kucher N. Clinical practice. Deep-vein thrombosis of the upper extremities. N Engl J Med 2011; 364:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/27\">",
"      Urschel HC Jr, Patel AN. Surgery remains the most effective treatment for Paget-Schroetter syndrome: 50 years' experience. Ann Thorac Surg 2008; 86:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/28\">",
"      Joffe HV, Goldhaber SZ. Upper-extremity deep vein thrombosis. Circulation 2002; 106:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/29\">",
"      Adams JT, DeWeese JA. \"Effort\" thrombosis of the axillary and subclavian veins. J Trauma 1971; 11:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/30\">",
"      Prandoni P, Bernardi E. Upper extremity deep vein thrombosis. Curr Opin Pulm Med 1999; 5:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/31\">",
"      Joffe HV, Kucher N, Tapson VF, et al. Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation 2004; 110:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/32\">",
"      Oz&ccedil;akar L, D&ouml;nmez G, Y&ouml;r&uuml;bulut M, et al. Paget-Schroetter syndrome forerunning the diagnoses of thoracic outlet syndrome and thrombophilia. Clin Appl Thromb Hemost 2010; 16:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/33\">",
"      Bolitho DG, Elwood ET, Roberts F. Phlegmasia cerulea dolens of the upper extremity. Ann Plast Surg 2000; 45:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/34\">",
"      Petritsch B, Wendel F, Hahn D, Goltz JP. Phlegmasia cerulea dolens of the arm. J Vasc Access 2012; 13:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/35\">",
"      Kucher N, Tapson VF, Goldhaber SZ, DVT FREE Steering Committee. Risk factors associated with symptomatic pulmonary embolism in a large cohort of deep vein thrombosis patients. Thromb Haemost 2005; 93:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/36\">",
"      Mu&ntilde;oz FJ, Mismetti P, Poggio R, et al. Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. Chest 2008; 133:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/37\">",
"      Stein PD, Matta F, Musani MH, Diaczok B. Silent pulmonary embolism in patients with deep venous thrombosis: a systematic review. Am J Med 2010; 123:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/38\">",
"      Mai C, Hunt D. Upper-extremity deep venous thrombosis: a review. Am J Med 2011; 124:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/39\">",
"      Inoue K, Saito J, Miyazaki M, et al. A Kendo player with haemoptysis. Lancet 2004; 364:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/40\">",
"      Urschel HC Jr, Patel AN. Paget-Schroetter syndrome therapy: failure of intravenous stents. Ann Thorac Surg 2003; 75:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/41\">",
"      Merminod T, Pellicciotta S, Bounameaux H. Limited usefulness of D-dimer in suspected deep vein thrombosis of the upper extremities. Blood Coagul Fibrinolysis 2006; 17:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/42\">",
"      Di Nisio M, Van Sluis GL, Bossuyt PM, et al. Accuracy of diagnostic tests for clinically suspected upper extremity deep vein thrombosis: a systematic review. J Thromb Haemost 2010; 8:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/43\">",
"      Kerr TM, Lutter KS, Moeller DM, et al. Upper extremity venous thrombosis diagnosed by duplex scanning. Am J Surg 1990; 160:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/44\">",
"      Knudson GJ, Wiedmeyer DA, Erickson SJ, et al. Color Doppler sonographic imaging in the assessment of upper-extremity deep venous thrombosis. AJR Am J Roentgenol 1990; 154:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/45\">",
"      Sajid MS, Ahmed N, Desai M, et al. Upper limb deep vein thrombosis: a literature review to streamline the protocol for management. Acta Haematol 2007; 118:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/46\">",
"      Prandoni P, Polistena P, Bernardi E, et al. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med 1997; 157:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/47\">",
"      Baarslag HJ, van Beek EJ, Koopman MM, Reekers JA. Prospective study of color duplex ultrasonography compared with contrast venography in patients suspected of having deep venous thrombosis of the upper extremities. Ann Intern Med 2002; 136:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/48\">",
"      Mustafa BO, Rathbun SW, Whitsett TL, Raskob GE. Sensitivity and specificity of ultrasonography in the diagnosis of upper extremity deep vein thrombosis: a systematic review. Arch Intern Med 2002; 162:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/49\">",
"      Chin EE, Zimmerman PT, Grant EG. Sonographic evaluation of upper extremity deep venous thrombosis. J Ultrasound Med 2005; 24:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/50\">",
"      H&uuml;bsch PJ, Stiglbauer RL, Schwaighofer BW, et al. Internal jugular and subclavian vein thrombosis caused by central venous catheters. Evaluation using Doppler blood flow imaging. J Ultrasound Med 1988; 7:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/51\">",
"      Haire WD, Lynch TG, Lund GB, et al. Limitations of magnetic resonance imaging and ultrasound-directed (duplex) scanning in the diagnosis of subclavian vein thrombosis. J Vasc Surg 1991; 13:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/52\">",
"      Desjardins B, Rybicki FJ, Kim HS, et al. ACR Appropriateness Criteria&reg; Suspected upper extremity deep vein thrombosis. J Am Coll Radiol 2012; 9:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/53\">",
"      Matsumura JS, Rilling WS, Pearce WH, et al. Helical computed tomography of the normal thoracic outlet. J Vasc Surg 1997; 26:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/54\">",
"      Kroencke TJ, Taupitz M, Arnold R, et al. Three-dimensional gadolinium-enhanced magnetic resonance venography in suspected thrombo-occlusive disease of the central chest veins. Chest 2001; 120:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/55\">",
"      Baarslag HJ, Van Beek EJ, Reekers JA. Magnetic resonance venography in consecutive patients with suspected deep vein thrombosis of the upper extremity: initial experience. Acta Radiol 2004; 45:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/56\">",
"      Kim H, Chung JW, Park JH, et al. Role of CT venography in the diagnosis and treatment of benign thoracic central venous obstruction. Korean J Radiol 2003; 4:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/57\">",
"      Sanders RJ, Hammond SL, Rao NM. Diagnosis of thoracic outlet syndrome. J Vasc Surg 2007; 46:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/58\">",
"      Girolami A, Prandoni P, Zanon E, et al. Venous thromboses of upper limbs are more frequently associated with occult cancer as compared with those of lower limbs. Blood Coagul Fibrinolysis 1999; 10:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/59\">",
"      Becker DM, Philbrick JT, Walker FB 4th. Axillary and subclavian venous thrombosis. Prognosis and treatment. Arch Intern Med 1991; 151:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/60\">",
"      Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/61\">",
"      Machleder HI. Evaluation of a new treatment strategy for Paget-Schroetter syndrome: spontaneous thrombosis of the axillary-subclavian vein. J Vasc Surg 1993; 17:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/62\">",
"      Rathbun SW, Stoner JA, Whitsett TL. Treatment of upper-extremity deep vein thrombosis. J Thromb Haemost 2011; 9:1924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/63\">",
"      Thompson JF, Winterborn RJ, Bays S, et al. Venous thoracic outlet compression and the Paget-Schroetter syndrome: a review and recommendations for management. Cardiovasc Intervent Radiol 2011; 34:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/64\">",
"      Stone DH, Scali ST, Bjerk AA, et al. Aggressive treatment of idiopathic axillo-subclavian vein thrombosis provides excellent long-term function. J Vasc Surg 2010; 52:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/65\">",
"      Lee WA, Hill BB, Harris EJ Jr, et al. Surgical intervention is not required for all patients with subclavian vein thrombosis. J Vasc Surg 2000; 32:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/66\">",
"      Melby SJ, Vedantham S, Narra VR, et al. Comprehensive surgical management of the competitive athlete with effort thrombosis of the subclavian vein (Paget-Schroetter syndrome). J Vasc Surg 2008; 47:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/67\">",
"      Strange-Vognsen HH, Hauch O, Andersen J, Struckmann J. Resection of the first rib, following deep arm vein thrombolysis in patients with thoracic outlet syndrome. J Cardiovasc Surg (Torino) 1989; 30:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/68\">",
"      de Le&oacute;n RA, Chang DC, Hassoun HT, et al. Multiple treatment algorithms for successful outcomes in venous thoracic outlet syndrome. Surgery 2009; 145:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/69\">",
"      Urschel HC Jr, Razzuk MA. Improved management of the Paget-Schroetter syndrome secondary to thoracic outlet compression. Ann Thorac Surg 1991; 52:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/70\">",
"      Donayre CE, White GH, Mehringer SM, Wilson SE. Pathogenesis determines late morbidity of axillosubclavian vein thrombosis. Am J Surg 1986; 152:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/71\">",
"      AbuRahma AF, Sadler D, Stuart P, et al. Conventional versus thrombolytic therapy in spontaneous (effort) axillary-subclavian vein thrombosis. Am J Surg 1991; 161:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/72\">",
"      Skalicka L, Lubanda JC, Jirat S, et al. Endovascular treatment combined with stratified surgery is effective in the management of venous thoracic outlet syndrome complications: a long term ultrasound follow-up study in patients with thrombotic events due to venous thoracic outlet syndrome. Heart Vessels 2011; 26:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/73\">",
"      Lee MC, Grassi CJ, Belkin M, et al. Early operative intervention after thrombolytic therapy for primary subclavian vein thrombosis: an effective treatment approach. J Vasc Surg 1998; 27:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/74\">",
"      Gloviczki P, Kazmier FJ, Hollier LH. Axillary-subclavian venous occlusion: the morbidity of a nonlethal disease. J Vasc Surg 1986; 4:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/75\">",
"      Prandoni P, Bernardi E, Marchiori A, et al. The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort study. BMJ 2004; 329:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/76\">",
"      Povlsen B, Belzberg A, Hansson T, Dorsi M. Treatment for thoracic outlet syndrome. Cochrane Database Syst Rev 2010; :CD007218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/77\">",
"      Molina JE, Hunter DW, Dietz CA. Protocols for Paget-Schroetter syndrome and late treatment of chronic subclavian vein obstruction. Ann Thorac Surg 2009; 87:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/78\">",
"      Urschel HC Jr, Razzuk MA. Neurovascular compression in the thoracic outlet: changing management over 50 years. Ann Surg 1998; 228:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/79\">",
"      Hrub&yacute; J, Semr&aacute;d M, Vidim T, et al. [Outcomes of combined surgical and endovascular treatment of the venous thoracic outlet syndrome during 2000-2007 in the IInd Surgical Clinic of the VFN (General Faculty Hospital) and 1. LF UK (First Medical Faculty, Charles University) in Prague]. Rozhl Chir 2010; 89:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/80\">",
"      Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:454S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/81\">",
"      Angle N, Gelabert HA, Farooq MM, et al. Safety and efficacy of early surgical decompression of the thoracic outlet for Paget-Schroetter syndrome. Ann Vasc Surg 2001; 15:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/82\">",
"      Vik A, Holme PA, Singh K, et al. Catheter-directed thrombolysis for treatment of deep venous thrombosis in the upper extremities. Cardiovasc Intervent Radiol 2009; 32:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/83\">",
"      Lee JT, Karwowski JK, Harris EJ, et al. Long-term thrombotic recurrence after nonoperative management of Paget-Schroetter syndrome. J Vasc Surg 2006; 43:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/84\">",
"      Molina JE, Hunter DW, Dietz CA. Paget-Schroetter syndrome treated with thrombolytics and immediate surgery. J Vasc Surg 2007; 45:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/85\">",
"      Schneider DB, Dimuzio PJ, Martin ND, et al. Combination treatment of venous thoracic outlet syndrome: open surgical decompression and intraoperative angioplasty. J Vasc Surg 2004; 40:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/86\">",
"      Guzzo JL, Chang K, Demos J, et al. Preoperative thrombolysis and venoplasty affords no benefit in patency following first rib resection and scalenectomy for subacute and chronic subclavian vein thrombosis. J Vasc Surg 2010; 52:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/87\">",
"      Tilney ML, Griffiths HJ, Edwards EA. Natural history of major venous thrombosis of the upper extremity. Arch Surg 1970; 101:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/88\">",
"      van Dongen CJ, van den Belt AG, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004; :CD001100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/89\">",
"      Karabay O, Yetkin U, Onol H. Upper extremity deep vein thrombosis: clinical and treatment characteristics. J Int Med Res 2004; 32:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/90\">",
"      Savage KJ, Wells PS, Schulz V, et al. Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity. Thromb Haemost 1999; 82:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/91\">",
"      Enden T, Sandvik L, Kl&oslash;w NE, et al. Catheter-directed Venous Thrombolysis in acute iliofemoral vein thrombosis--the CaVenT study: rationale and design of a multicenter, randomized, controlled, clinical trial (NCT00251771). Am Heart J 2007; 154:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/92\">",
"      Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:257S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/93\">",
"      Caparrelli DJ, Freischlag J. A unified approach to axillosubclavian venous thrombosis in a single hospital admission. Semin Vasc Surg 2005; 18:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/94\">",
"      Alesh I, Kayali F, Stein PD. Catheter-directed thrombolysis (intrathrombus injection) in treatment of deep venous thrombosis: a systematic review. Catheter Cardiovasc Interv 2007; 70:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/95\">",
"      Shah AD, Bajakian DR, Olin JW, Lookstein RA. Power-pulse spray thrombectomy for treatment of Paget-Schroetter syndrome. AJR Am J Roentgenol 2007; 188:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/96\">",
"      Oklu R, Wicky S. Catheter-Directed Thrombolysis of Deep Venous Thrombosis. Semin Thromb Hemost 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/97\">",
"      Wicky ST. Acute deep vein thrombosis and thrombolysis. Tech Vasc Interv Radiol 2009; 12:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/98\">",
"      Kim HS, Patra A, Paxton BE, et al. Catheter-directed thrombolysis with percutaneous rheolytic thrombectomy versus thrombolysis alone in upper and lower extremity deep vein thrombosis. Cardiovasc Intervent Radiol 2006; 29:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/99\">",
"      Dasari TW, Pappy R, Hennebry TA. Pharmacomechanical thrombolysis of acute and chronic symptomatic deep vein thrombosis: a systematic review of literature. Angiology 2012; 63:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/100\">",
"      Urschel HC Jr. Management of the thoracic-outlet syndrome. N Engl J Med 1972; 286:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/101\">",
"      Molina JE. Surgery for effort thrombosis of the subclavian vein. J Thorac Cardiovasc Surg 1992; 103:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/102\">",
"      Chang KZ, Likes K, Demos J, et al. Routine venography following transaxillary first rib resection and scalenectomy (FRRS) for chronic subclavian vein thrombosis ensures excellent outcomes and vein patency. Vasc Endovascular Surg 2012; 46:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/103\">",
"      Feugier P, Aleksic I, Salari R, et al. Long-term results of venous revascularization for Paget-Schroetter syndrome in athletes. Ann Vasc Surg 2001; 15:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/104\">",
"      Meier GH, Pollak JS, Rosenblatt M, et al. Initial experience with venous stents in exertional axillary-subclavian vein thrombosis. J Vasc Surg 1996; 24:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/105\">",
"      Oderich GS, Treiman GS, Schneider P, Bhirangi K. Stent placement for treatment of central and peripheral venous obstruction: a long-term multi-institutional experience. J Vasc Surg 2000; 32:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/106\">",
"      Maintz D, Landwehr P, Gawenda M, Lackner K. Failure of Wallstents in the subclavian vein due to stent damage. Clin Imaging 2001; 25:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/107\">",
"      Schulman S, Lindmarker P, Holmstr&ouml;m M, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006; 4:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/108\">",
"      Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000; 160:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/109\">",
"      Molina JE. Reoperations after failed transaxillary first rib resection to treat Paget-Schroetter syndrome patients. Ann Thorac Surg 2011; 91:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/110\">",
"      Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Doggen CJ. Recurrent thrombosis and survival after a first venous thrombosis of the upper extremity. Circulation 2008; 118:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/111\">",
"      Gabriel F, Portol&eacute;s O, Labi&oacute;s M, et al. Usefulness of thrombophilia testing in venous thromboembolic disease: findings from the RIETE registry. Clin Appl Thromb Hemost 2013; 19:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/112\">",
"      Cassada DC, Lipscomb AL, Stevens SL, et al. The importance of thrombophilia in the treatment of Paget-Schroetter syndrome. Ann Vasc Surg 2006; 20:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/113\">",
"      Martinelli I, Battaglioli T, Bucciarelli P, et al. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Circulation 2004; 110:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/114\">",
"      Leebeek FW, Stadhouders NA, van Stein D, et al. Hypercoagulability states in upper-extremity deep venous thrombosis. Am J Hematol 2001; 67:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/115\">",
"      H&eacute;ron E, Lozinguez O, Alhenc-Gelas M, et al. Hypercoagulable states in primary upper-extremity deep vein thrombosis. Arch Intern Med 2000; 160:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/6/27754/abstract/116\">",
"      Persson LM, Arnhjort T, L&auml;rfars G, Rosfors S. Hemodynamic and morphologic evaluation of sequelae of primary upper extremity deep venous thromboses treated with anticoagulation. J Vasc Surg 2006; 43:1230.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8211 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_6_27754=[""].join("\n");
var outline_f27_6_27754=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H93841183\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H185996549\">",
"      UPPER EXTREMITY ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H185996601\">",
"      Superficial veins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H185996608\">",
"      Deep veins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H186006964\">",
"      Thoracic outlet anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H239061107\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H239061271\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H239061389\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL PRESENTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H351070\">",
"      Acute upper extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H351144\">",
"      Acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H351151\">",
"      Chronic or intermittent symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H185997417\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1387789930\">",
"      D-dimer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H239062098\">",
"      Venous outflow obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H239062150\">",
"      Anatomic abnormalities of the thoracic outlet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25075587\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H239066343\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H352775\">",
"      Rationale for aggressive treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1387792888\">",
"      Recommendations of others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H239064139\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H239065433\">",
"      Symptomatic care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H239064388\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H239067075\">",
"      Admission and referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H185996469\">",
"      THROMBOLYTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H185996871\">",
"      THORACIC OUTLET DECOMPRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H239067437\">",
"      VENOPLASTY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H185997649\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H354750291\">",
"      Duration of anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H239068450\">",
"      PERIOPERATIVE MORBIDITY AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112510524\">",
"      Recurrent thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H185996348\">",
"      Post-thrombotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93841183\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8211\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8211|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/3/18480\" title=\"figure 1\">",
"      Anterior view superficial veins of the upper extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/43/16053\" title=\"figure 2\">",
"      Deep veins of the upper extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/58/18338\" title=\"figure 3A\">",
"      Anatomy of the thoracic outlet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/46/39650\" title=\"figure 3B\">",
"      Cervical rib causing thoracic outlet syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8211|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/28/4555\" title=\"table 1\">",
"      Contraindications to thrombolytic therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=related_link\">",
"      Catheter-induced upper extremity venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34375?source=related_link\">",
"      Clinical manifestations and diagnosis of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3177?source=related_link\">",
"      Overview of thoracic outlet syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/34/36393?source=related_link\">",
"      Pathophysiology and etiology of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23127?source=related_link\">",
"      Post-thrombotic (postphlebitic) syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=related_link\">",
"      Screening for inherited thrombophilia in asymptomatic populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_6_27755="Heterozyg comp def";
var content_f27_6_27755=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F72700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F72700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Inherited partial (heterozygous) defects and polymorphisms of complement proteins leading to human disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Defective protein(s)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Associated illnesses",
"      </td>",
"      <td class=\"subtitle1\">",
"       Mechanism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Factor H*",
"      </td>",
"      <td>",
"       aHUS; AMD; HELLP",
"      </td>",
"      <td>",
"       Excessive AP activation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Factor I*",
"      </td>",
"      <td>",
"       aHUS: HELLP",
"      </td>",
"      <td>",
"       Excessive AP activation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       MCP (CD46)*",
"      </td>",
"      <td>",
"       aHUS; HELLP",
"      </td>",
"      <td>",
"       Excessive AP activation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Factor B&bull;",
"      </td>",
"      <td>",
"       aHUS; AMD",
"      </td>",
"      <td>",
"       Excessive AP activation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       C3&bull;",
"      </td>",
"      <td>",
"       aHUS, AMD",
"      </td>",
"      <td>",
"       Excessive AP activation",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     aHUS: atypical hemolytic uremic syndrome; AMD: age-related macular degeneration; HELLP: hemolytic anemia, elevated liver enzymes and low platelet count; AP: alternative pathway; MCP: membrane cofactor protein.",
"     <br>",
"      * Decreased regulatory activity secondary to being haploinsufficient (lack of protein production or a functionally deficient protein)",
"      <br>",
"       &bull; Gain of function mutations lead to increased alternative pathway activity.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of M. Liszewski and Dr. John P. Atkinson.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_6_27755=[""].join("\n");
var outline_f27_6_27755=null;
var title_f27_6_27756="Radiation fields in HL";
var content_f27_6_27756=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Definition of radiation fields in Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Anatomic definitions of separate lymph node regions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Waldeyer's ring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical, supraclavicular, occipital, and preauricular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infraclavicular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Axillary and pectoral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mediastinal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hilar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epitrochlear and brachial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spleen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paraaortic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesenteric",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iliac (pelvic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inguinal and femoral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Popliteal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Functional radiation field definitions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Involved field",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\">",
"        An involved field includes not only the individual clinically involved",
"or enlarged node(s) but also the other lymph nodes within the same",
"lymph node region (see above). The involved field is the minimum",
"radiation field size used for Hodgkin lymphoma.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Extended field",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        An extended field includes the involved field (see above) as well as all",
"        <strong>",
"         immediately",
"        </strong>",
"        adjacent lymph node regions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Mantle field",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The mantle field includes all of the supradiaphragmatic lymph nodes commonly involved in Hodgkin lymphoma (see below).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Inverted-Y field",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The inverted-Y field is a combination of paraaortic, iliac (pelvic),",
"and inguinal-femoral fields, with or without the splenic field (see",
"below).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Total nodal irradiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Total nodal irradiation implies treatment of all major lymph node",
"regions above and below the diaphragm; typically a mantle field plus an",
"inverted-Y field. It is important to note that certain lymph node",
"groups are rarely involved in Hodgkin lymphoma and are not included in",
"these fields. These include brachial, epitrochlear, popliteal, sacral",
"and mesenteric nodes.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_6_27756=[""].join("\n");
var outline_f27_6_27756=null;
var title_f27_6_27757="Cases of NSF reported to the USFDA AERS";
var content_f27_6_27757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F86395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F86395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 634px\">",
"   <div class=\"ttl\">",
"    The number of cases of nephrogenic systemic fibrosis reported to the US Food and Drug Administration, adverse events reporting system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 614px; height: 222px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The number of cases reported to the US Food and Drug Administration's adverse events reporting system declined in 2011.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Ira Krefting, FDA presented at: 5th Annual Scientific Symposium on Nephrogenic Systemic Fibrosis and Allied Fibrotic Disorders. May 20, 2011 at the Yale University School of Medicine, New Haven, CT.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_6_27757=[""].join("\n");
var outline_f27_6_27757=null;
var title_f27_6_27758="VCUG PUV dilated post ureth";
var content_f27_6_27758=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Voiding cystourethogram of a patient with posterior urethral valves",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Voiding cystourethrogram of patient with posterior urethral valves noted by white arrows with dilated posterior urethra. Small capacity bladder with vesicoureteral reflux (black arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nicholas Holmes, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_6_27758=[""].join("\n");
var outline_f27_6_27758=null;
var title_f27_6_27759="Median nerve block";
var content_f27_6_27759=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Median nerve block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The wrist is placed in the palm up position, dorsiflexed to 30 degrees. Ethyl chloride is applied to the skin for anesthesia. A 5/8 inch, 25-gauge needle is inserted on the palmaris longus at the most distal volar wrist crease at a 45-degree angle to a depth of 1/2 to 5/8 inch. 1/4 mL of lidocaine is injected subcutaneously and 1/2 to 1 mL in the tunnel. Note: Injection should only be performed by physicians with specific training in carpal tunnel injection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_6_27759=[""].join("\n");
var outline_f27_6_27759=null;
